Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	B-protein
-induced	O
signal	O
transduction	O
.	O

Erythropoietin	B-protein
(	O
EPO	B-protein
)	O
and	O
its	O
receptor	O
(	O
EPOR	B-protein
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O

After	O
binding	O
of	O
ligand	O
,	O
the	O
EPOR	B-protein
activates	O
a	O
variety	O
of	O
signaling	O
pathways	O
that	O
ultimately	O
control	O
cellular	O
proliferation	O
,	O
survival	O
,	O
and	O
specific	O
gene	O
expression	O
.	O

Although	O
erythroid	B-cell_type
progenitors	I-cell_type
appear	O
to	O
be	O
the	O
principal	O
EPO-responsive	B-cell_type
cell	I-cell_type
type	I-cell_type
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	B-protein
,	O
many	O
growth	B-cell_line
factor-dependent	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
EPOR	B-protein
can	O
respond	O
to	O
EPO	B-protein
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin-2	B-cell_line
[	I-cell_line
IL-2	I-cell_line
]	I-cell_line
-dependent	I-cell_line
HT-2	I-cell_line
line	I-cell_line
)	O
in	O
which	O
the	O
EPO	B-protein
stimulation	O
of	O
the	O
EPOR	B-protein
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT-5	B-protein
induction	O
,	O
or	O
MAPK	B-protein
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	B-protein
and	O
JAK2	B-protein
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL-2	B-protein
.	O

Interestingly	O
,	O
when	O
we	O
fused	O
HT-2	B-cell_line
cells	I-cell_line
expressing	O
the	O
EPOR	B-protein
with	O
Ba/F3	B-cell_line
cells	I-cell_line
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	B-cell_line
proliferated	O
and	O
potently	O
activated	O
STAT-5	B-protein
and	O
MAPK	B-protein
in	O
response	O
to	O
EPO	B-protein
.	O

These	O
data	O
indicate	O
that	O
an	O
unidentified	B-protein
cellular	I-protein
factor	I-protein
is	O
needed	O
to	O
mediate	O
signaling	O
by	O
the	O
EPOR	B-protein
.	O

Moreover	O
,	O
Ba/F3	B-cell_line
cells	I-cell_line
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	B-protein
-responsiveness	O
to	O
HT-2	B-cell_line
cells	I-cell_line
that	O
lack	O
this	O
factor	O
.	O

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

HEMATOPOIESIS	NULL
Genetic	NULL
Evidence	NULL
for	NULL
an	NULL
Additional	NULL
Factor	NULL
Required	NULL
for	NULL
Erythropoietin-Induced	NULL
Signal	NULL
Transduction	NULL
By	NULL
Sarah	NULL
L.	NULL
Gaffen	NULL
,	NULL
Stephen	NULL
Y.	NULL
Lai	NULL
,	NULL
Gregory	NULL
D.	NULL
Longmore	NULL
,	NULL
Kathleen	NULL
D.	NULL
Liu	NULL
,	NULL
and	NULL
Mark	NULL
A.	NULL
Goldsmith	NULL
Erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
and	NULL
its	NULL
receptor	NULL
(	NULL
EPOR	NULL
)	NULL
are	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
mature	NULL
erythrocytes	NULL
.	NULL

After	NULL
binding	NULL
of	NULL
ligand	NULL
,	NULL
the	NULL
EPOR	NULL
activates	NULL
a	NULL
variety	NULL
of	NULL
signaling	NULL
pathways	NULL
that	NULL
ultimately	NULL
control	NULL
cellular	NULL
proliferation	NULL
,	NULL
survival	NULL
,	NULL
and	NULL
specific	NULL
gene	NULL
expression	NULL
.	NULL

Although	NULL
erythroid	NULL
progenitors	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
principal	NULL
EPO-responsive	NULL
cell	NULL
type	NULL
in	NULL
vivo	NULL
due	NULL
to	NULL
the	NULL
restricted	NULL
expression	NULL
of	NULL
the	NULL
EPOR	NULL
,	NULL
many	NULL
growth	NULL
factor-dependent	NULL
cell	NULL
lines	NULL
expressing	NULL
the	NULL
EPOR	NULL
can	NULL
respond	NULL
to	NULL
EPO	NULL
by	NULL
activating	NULL
many	NULL
or	NULL
all	NULL
of	NULL
these	NULL
pathways	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
a	NULL
cellular	NULL
context	NULL
(	NULL
the	NULL
interleukin-2	NULL
[	NULL
IL-2	NULL
]	NULL
-dependent	NULL
HT-2	NULL
line	NULL
)	NULL
in	NULL
which	NULL
the	NULL
EPO	NULL
stimulation	NULL
of	NULL
the	NULL
EPOR	NULL
fails	NULL
to	NULL
support	NULL
cellular	NULL
proliferation	NULL
,	NULL
AMMALIAN	NULL
BLOOD	NULL
CELL	NULL
differentiation	NULL
depends	NULL
on	NULL
cellular	NULL
proliferation	NULL
and	NULL
crucial	NULL
cell-fate	NULL
decisions	NULL
that	NULL
are	NULL
coordinated	NULL
by	NULL
a	NULL
family	NULL
of	NULL
hematopoietic	NULL
cytokines	NULL
,	NULL
particularly	NULL
erythropoietin	NULL
(	NULL
EPO	NULL
)	NULL
.	NULL

EPO	NULL
,	NULL
a	NULL
34-kD	NULL
cytokine	NULL
,	NULL
is	NULL
produced	NULL
by	NULL
the	NULL
kidney	NULL
under	NULL
conditions	NULL
of	NULL
low	NULL
oxygen	NULL
tension	NULL
and	NULL
acts	NULL
on	NULL
erythroid	NULL
progenitors	NULL
via	NULL
a	NULL
specific	NULL
erythropoietin	NULL
receptor	NULL
(	NULL
EPOR	NULL
)	NULL
.	NULL

!	NULL

EPO	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
mammalian	NULL
hematopoi-esis	NULL
,	NULL
because	NULL
it	NULL
is	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
mature	NULL
erythrocytes	NULL
,	NULL
and	NULL
animals	NULL
deficient	NULL
in	NULL
this	NULL
cytokine	NULL
or	NULL
its	NULL
receptor	NULL
die	NULL
early	NULL
in	NULL
fetal	NULL
development	NULL
due	NULL
to	NULL
severe	NULL
anemia	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
EPO	NULL
is	NULL
used	NULL
extensively	NULL
in	NULL
the	NULL
clinic	NULL
to	NULL
treat	NULL
anemia	NULL
associated	NULL
with	NULL
EPO	NULL
deficiency	NULL
without	NULL
serious	NULL
side	NULL
effects	NULL
.	NULL

Numerous	NULL
signaling	NULL
molecules	NULL
and	NULL
pathways	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
the	NULL
EPOR	NULL
,	NULL
the	NULL
combined	NULL
effects	NULL
of	NULL
which	NULL
generally	NULL
include	NULL
cellular	NULL
survival	NULL
and/or	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
specific	NULL
gene	NULL
expression	NULL
,	NULL
ultimately	NULL
leading	NULL
to	NULL
erythroid	NULL
maturation	NULL
and	NULL
expansion	NULL
of	NULL
the	NULL
red	NULL
blood	NULL
cell	NULL
compartment	NULL
.	NULL

*	NULL
The	NULL
EPOR	NULL
belongs	NULL
to	NULL
the	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
,	NULL
From	NULL
the	NULL
Gladstone	NULL
Institute	NULL
of	NULL
Virology	NULL
and	NULL
Immunology	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
;	NULL
the	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
;	NULL
and	NULL
the	NULL
Departments	NULL
of	NULL
Medicine	NULL
and	NULL
Cell	NULL
Biology	NULL
,	NULL
Washington	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
.	NULL

Submitted	NULL
August	NULL
24	NULL
,	NULL
1998	NULL
;	NULL
accepted	NULL
February	NULL
23	NULL
,	NULL
1999	NULL
.	NULL

Supported	NULL
by	NULL
the	NULL
J.	NULL
David	NULL
Gladstone	NULL
Institutes	NULL
,	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
Granis	NULL
No	NULL
.	NULL

GM54351	NULL
to	NULL
M.A.G	NULL
.	NULL

and	NULL
CA75315	NULL
to	NULL
G.D.L	NULL
.	NULL

SL.G	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
Bank	NULL
of	NULL
America-Giannini	NULL
Foundation	NULL
and	NULL
the	NULL
NIH	NULL
Immunology	NULL
Training	NULL
Grant	NULL
at	NULL
the	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
.	NULL

S.Y.L	NULL
.	NULL

was	NULL
in	NULL
the	NULL
NIH	NULL
Medical	NULL
Scientist	NULL
Training	NULL
Program	NULL
(	NULL
MSTP	NULL
)	NULL
and	NULL
the	NULL
Biomedical	NULL
Sciences	NULL
Program	NULL
at	NULL
the	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
(	NULL
UCSF	NULL
)	NULL
,	NULL
and	NULL
KD.L	NULL
.	NULL

is	NULL
in	NULL
the	NULL
NIH	NULL
MSTP	NULL
and	NULL
Program	NULL
in	NULL
Biological	NULL
Sciences	NULL
at	NULL
UCSF	NULL
Address	NULL
reprint	NULL
requests	NULL
to	NULL
Mark	NULL
A.	NULL
Goldsmith	NULL
,	NULL
MD	NULL
,	NULL
PhD	NULL
,	NULL
Gladstone	NULL
Institute	NULL
of	NULL
Virology	NULL
and	NULL
Immunology	NULL
,	NULL
PO	NULL
Box	NULL
419100	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
94141	NULL
;	NULL
e-mail	NULL
:	NULL
mgoldsmith	NULL
@	NULL
gladstone.ucsf.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/99/9401-00408	NULL
$	NULL
3.00/0	NULL
74	NULL
STAT-5	NULL
induction	NULL
,	NULL
or	NULL
M	NULL
APK	NULL
activation	NULL
,	NULL
despite	NULL
efficient	NULL
phosphorylation	NULL
of	NULL
the	NULL
EPOR	NULL
and	NULL
JAK2	NULL
and	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
after	NULL
withdrawal	NULL
of	NULL
IL-2	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
we	NULL
fused	NULL
HT-2	NULL
cells	NULL
expressing	NULL
the	NULL
EPOR	NULL
with	NULL
Ba/	NULL
F3	NULL
cells	NULL
in	NULL
a	NULL
complementation	NULL
assay	NULL
,	NULL
the	NULL
resulting	NULL
hybridomas	NULL
proliferated	NULL
and	NULL
potently	NULL
activated	NULL
STAT-5	NULL
and	NULL
MAPK	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
an	NULL
unidentified	NULL
cellular	NULL
factor	NULL
is	NULL
needed	NULL
to	NULL
mediate	NULL
signaling	NULL
by	NULL
the	NULL
EPOR	NULL
.	NULL

Moreover	NULL
,	NULL
Ba/	NULL
F3	NULL
cells	NULL
apparently	NULL
express	NULL
this	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
and	NULL
somatic	NULL
fusions	NULL
can	NULL
,	NULL
therefore	NULL
,	NULL
confer	NULL
EPO-responsiveness	NULL
to	NULL
HT-2	NULL
cells	NULL
that	NULL
lack	NULL
this	NULL
factor	NULL
.	NULL

©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

members	NULL
of	NULL
which	NULL
are	NULL
characterized	NULL
by	NULL
conserved	NULL
structural	NULL
motifs	NULL
in	NULL
the	NULL
extracellular	NULL
domain	NULL
including	NULL
four	NULL
conserved	NULL
cysteine	NULL
residues	NULL
and	NULL
a	NULL
membrane-proximal	NULL
WSXWS	NULL
motif	NULL
.	NULL
``	NULL

Like	NULL
other	NULL
members	NULL
of	NULL
this	NULL
family	NULL
,	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
EPOR	NULL
contains	NULL
no	NULL
known	NULL
enzymatic	NULL
activity	NULL
,	NULL
but	NULL
instead	NULL
associates	NULL
with	NULL
various	NULL
second	NULL
messenger	NULL
molecules	NULL
to	NULL
effect	NULL
signal	NULL
transduction	NULL
.	NULL

EPO	NULL
stimulation	NULL
is	NULL
thought	NULL
to	NULL
trigger	NULL
homodimerization	NULL
of	NULL
EPOR	NULL
subunits	NULL
,	NULL
initiating	NULL
a	NULL
cascade	NULL
of	NULL
signal	NULL
transduction	NULL
events	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
mutation	NULL
within	NULL
the	NULL
EPOR	NULL
extracellular	NULL
region	NULL
of	NULL
cysteine	NULL
for	NULL
arginine-129	NULL
results	NULL
in	NULL
constitutive	NULL
dimerization	NULL
through	NULL
a	NULL
disulfide	NULL
bridge	NULL
between	NULL
receptor	NULL
subunits	NULL
that	NULL
causes	NULL
ligand-independent	NULL
signaling	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
synthetic	NULL
peptide	NULL
dimers	NULL
that	NULL
cause	NULL
dimerization	NULL
of	NULL
the	NULL
EPOR	NULL
function	NULL
similarly	NULL
to	NULL
EPO	NULL
,	NULL
and	NULL
crystal	NULL
structures	NULL
of	NULL
the	NULL
EPOR	NULL
co-complexed	NULL
with	NULL
these	NULL
peptides	NULL
show	NULL
that	NULL
the	NULL
receptor	NULL
adapts	NULL
a	NULL
symmetrical	NULL
twofold	NULL
dimer	NULL
configuration	NULL
.	NULL
``	NULL

Homodimerization	NULL
of	NULL
the	NULL
receptor	NULL
results	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
intracellular	NULL
substrates	NULL
,	NULL
including	NULL
the	NULL
EPOR	NULL
itself	NULL
.	NULL
``	NULL

''	NULL
Tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
receptor	NULL
and	NULL
many	NULL
of	NULL
its	NULL
associated	NULL
signaling	NULL
molecules	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
Janus	NULL
kinase	NULL
JAK2	NULL
,	NULL
which	NULL
associates	NULL
constitutively	NULL
with	NULL
EPOR	NULL
monomeric	NULL
subunits	NULL
and	NULL
is	NULL
activated	NULL
upon	NULL
ligand	NULL
binding	NULL
by	NULL
autophosphorylation	NULL
.	NULL

'*	NULL
One	NULL
consequence	NULL
of	NULL
JAK2	NULL
activation	NULL
is	NULL
the	NULL
recruitment	NULL
of	NULL
the	NULL
SH2-domain-containing	NULL
transcription	NULL
factors	NULL
STAT-5A	NULL
and	NULL
This	NULL
recruitment	NULL
leads	NULL
to	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT-5A/5B	NULL
and	NULL
dimerization	NULL
via	NULL
reciprocal	NULL
SH2-phosphotyrosyl	NULL
interactions	NULL
,	NULL
followed	NULL
by	NULL
rapid	NULL
nuclear	NULL
import	NULL
of	NULL
STAT-5	NULL
dimers	NULL
,	NULL
resulting	NULL
in	NULL
transcription	NULL
of	NULL
EPO-responsive	NULL
genes	NULL
such	NULL
as	NULL
oncostatin-M	NULL
'	NULL
``	NULL
and	NULL
the	NULL
signaling	NULL
inhibitor	NULL
CIS	NULL
.	NULL
'	NULL

8	NULL
Studies	NULL
using	NULL
dominant	NULL
negative	NULL
STAT-5	NULL
mutants	NULL
or	NULL
EPOR	NULL
mutants	NULL
defective	NULL
in	NULL
STAT-S5-association	NULL
domains	NULL
have	NULL
linked	NULL
the	NULL
activation	NULL
of	NULL
STAT-5	NULL
to	NULL
cellular	NULL
proliferation	NULL
and/or	NULL
differentiation	NULL
in	NULL
certain	NULL
cultured	NULL
cell	NULL
lines	NULL
.	NULL

!	NULL
``	NULL

However	NULL
,	NULL
mice	NULL
deficient	NULL
in	NULL
STAT-5A	NULL
,	NULL
STAT-5B	NULL
,	NULL
or	NULL
both	NULL
exhibit	NULL
normal	NULL
erythropoiesis	NULL
,	NULL
``	NULL
indicating	NULL
that	NULL
STAT-5	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
EPOR	NULL
function	NULL
in	NULL
vivo	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
receptor	NULL
also	NULL
leads	NULL
to	NULL
the	NULL
recruitment	NULL
of	NULL
other	NULL
SH2-containing	NULL
proteins	NULL
such	NULL
as	NULL
Shc	NULL
,	NULL
PI3K	NULL
,	NULL
SHIP	NULL
,	NULL
Vav	NULL
,	NULL
and	NULL
PLCy	NULL
,	NULL
and	NULL
the	NULL
tyrosine	NULL
phosphatases	NULL
SHP-1	NULL
and	NULL
SHP-2.4	NULL
``	NULL
°	NULL
Therefore	NULL
,	NULL
the	NULL
EPOR	NULL
activates	NULL
a	NULL
striking	NULL
array	NULL
of	NULL
signaling	NULL
pathways	NULL
that	NULL
are	NULL
characteristic	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
and	NULL
act	NULL
in	NULL
concert	NULL
to	NULL
coordinate	NULL
the	NULL
physiological	NULL
effects	NULL
of	NULL
this	NULL
cytokine	NULL
.	NULL

Blood	NULL
,	NULL
Vol	NULL
94	NULL
,	NULL
No	NULL
1	NULL
(	NULL
July	NULL
1	NULL
)	NULL
,	NULL
1999	NULL
:	NULL
pp	NULL
74-86	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

ADDITIONAL	NULL
FACTOR	NULL
NEEDED	NULL
FOR	NULL
EPOR	NULL
SIGNALING	NULL
The	NULL
study	NULL
of	NULL
cytokine	NULL
signaling	NULL
pathways	NULL
has	NULL
been	NULL
aided	NULL
greatly	NULL
by	NULL
the	NULL
availability	NULL
of	NULL
cytokine-dependent	NULL
cell	NULL
lines	NULL
.	NULL

For	NULL
example	NULL
,	NULL
in	NULL
the	NULL
interleukin-3	NULL
(	NULL
IL-3	NULL
)	NULL
-dependent	NULL
cell	NULL
lines	NULL
32D	NULL
(	NULL
pro-myeloid	NULL
)	NULL
and	NULL
Ba/F3	NULL
(	NULL
pro-B	NULL
)	NULL
,	NULL
ectopic	NULL
expression	NULL
of	NULL
the	NULL
EPOR	NULL
allows	NULL
growth	NULL
in	NULL
EPO	NULL
in	NULL
place	NULL
of	NULL
IL-3	NULL
.	NULL

Similarly	NULL
,	NULL
transfection	NULL
of	NULL
the	NULL
IL-2RfB	NULL
chain	NULL
into	NULL
these	NULL
cell	NULL
lines	NULL
renders	NULL
them	NULL
responsive	NULL
to	NULL
IL-2	NULL
.	NULL
``	NULL

These	NULL
cell	NULL
lines	NULL
have	NULL
been	NULL
valuable	NULL
in	NULL
molecular	NULL
mapping	NULL
studies	NULL
of	NULL
the	NULL
EPOR	NULL
,	NULL
allowing	NULL
specific	NULL
signaling	NULL
events	NULL
to	NULL
be	NULL
linked	NULL
to	NULL
particular	NULL
subdomains	NULL
of	NULL
the	NULL
EPOR	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
such	NULL
studies	NULL
suggest	NULL
that	NULL
there	NULL
is	NULL
tremendous	NULL
overlap	NULL
in	NULL
the	NULL
array	NULL
of	NULL
signals	NULL
used	NULL
by	NULL
various	NULL
cytokine	NULL
receptors	NULL
.	NULL

For	NULL
example	NULL
,	NULL
in	NULL
the	NULL
32D	NULL
and	NULL
Ba/F3	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
EPOR	NULL
,	NULL
IL-2R	NULL
,	NULL
and	NULL
IL-3R	NULL
complexes	NULL
all	NULL
activate	NULL
JAKs	NULL
,	NULL
STAT-5A/B	NULL
,	NULL
the	NULL
MAPK	NULL
cascade	NULL
,	NULL
c-fos	NULL
gene	NULL
expression/	NULL
DNA	NULL
binding	NULL
,	NULL
be/-2	NULL
and	NULL
be/-x	NULL
;	NULL
gene	NULL
expression	NULL
,	NULL
and	NULL
inhibit	NULL
apoptosis	NULL
.	NULL

The	NULL
present	NULL
report	NULL
describes	NULL
a	NULL
cell	NULL
line	NULL
in	NULL
which	NULL
signaling	NULL
through	NULL
the	NULL
EPOR	NULL
is	NULL
markedly	NULL
but	NULL
selectively	NULL
impaired	NULL
,	NULL
while	NULL
signaling	NULL
through	NULL
the	NULL
IL-2R	NULL
is	NULL
intact	NULL
.	NULL

Although	NULL
the	NULL
EPOR	NULL
can	NULL
activate	NULL
JAK2	NULL
and	NULL
exert	NULL
a	NULL
potent	NULL
anti-apoptotic	NULL
effect	NULL
in	NULL
this	NULL
cellular	NULL
background	NULL
,	NULL
it	NULL
fails	NULL
to	NULL
activate	NULL
STAT-5	NULL
or	NULL
MAPK	NULL
,	NULL
or	NULL
to	NULL
support	NULL
EPO-dependent	NULL
proliferation	NULL
,	NULL
despite	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
IL-2R	NULL
to	NULL
engage	NULL
these	NULL
pathways	NULL
efficiently	NULL
.	NULL

Genetic	NULL
complementation	NULL
by	NULL
somatic	NULL
fusion	NULL
to	NULL
permissive	NULL
cells	NULL
rescues	NULL
signaling	NULL
,	NULL
indicating	NULL
that	NULL
a	NULL
missing	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
can	NULL
be	NULL
provided	NULL
in	NULL
frans	NULL
to	NULL
restore	NULL
full	NULL
EPOR	NULL
function	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
cell	NULL
line	NULL
provides	NULL
a	NULL
valuable	NULL
system	NULL
in	NULL
which	NULL
to	NULL
identify	NULL
previously	NULL
unrecognized	NULL
components	NULL
of	NULL
the	NULL
EPOR	NULL
signaling	NULL
pathway	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
,	NULL
preparation	NULL
of	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
cytokine	NULL
stimulations	NULL
.	NULL

HT-2	NULL
cells	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
[	NULL
ATCC	NULL
]	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithers-burg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
,	NULL
2	NULL
mmol/L	NULL
glutamine	NULL
,	NULL
0.05	NULL
mmol/L	NULL
2-mercaptoethanol	NULL
and	NULL
1	NULL
nmol/L	NULL
recombinant	NULL
IL-2	NULL
(	NULL
generously	NULL
supplied	NULL
by	NULL
Chiron	NULL
Corp	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

HT-2.EPOR.3	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
this	NULL
media	NULL
with	NULL
1	NULL
mg/mL	NULL
G418	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
.	NULL

HT-2EPOBy	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
this	NULL
media	NULL
with	NULL
EPO	NULL
(	NULL
5	NULL
U/mL	NULL
,	NULL
a	NULL
gift	NULL
of	NULL
Ortho	NULL
Biotech	NULL
,	NULL
Raritan	NULL
,	NULL
NJ	NULL
)	NULL
in	NULL
place	NULL
of	NULL
IL-2	NULL
.	NULL

HT-2	NULL
transfectant	NULL
cell	NULL
lines	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
.	NULL

``	NULL
*	NULL
``	NULL
Briefly	NULL
,	NULL
cells	NULL
were	NULL
electroporated	NULL
at	NULL
300	NULL
V/950	NULL
uF	NULL
and	NULL
cultured	NULL
without	NULL
selective	NULL
media	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

They	NULL
were	NULL
transferred	NULL
to	NULL
selective	NULL
media	NULL
and	NULL
monoclonal	NULL
lines	NULL
obtained	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

32D	NULL
and	NULL
Ba/F3	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
,	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
2	NULL
mmol/L	NULL
glutamine	NULL
,	NULL
0.05	NULL
mmol/L	NULL
2-mercaptocethanol	NULL
,	NULL
and	NULL
10	NULL
%	NULL
WEHI-3B	NULL
conditioned	NULL
medium	NULL
(	NULL
CM	NULL
)	NULL
as	NULL
a	NULL
source	NULL
of	NULL
IL-3	NULL
.	NULL

371.2	NULL
cells	NULL
are	NULL
32D	NULL
cells	NULL
that	NULL
stably	NULL
express	NULL
a	NULL
transgene	NULL
encoding	NULL
IRS-1,5°	NULL
and	NULL
were	NULL
also	NULL
maintained	NULL
in	NULL
this	NULL
media	NULL
.	NULL

HCDS57	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Iscove	NULL
's	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
,	NULL
20	NULL
%	NULL
FBS	NULL
,	NULL
2	NULL
mmol/L	NULL
glutamine	NULL
,	NULL
and	NULL
1	NULL
U/mL	NULL
EPO	NULL
.	NULL

For	NULL
cytokine	NULL
stimulations	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
stripped	NULL
with	NULL
a	NULL
30-second	NULL
incubation	NULL
in	NULL
10	NULL
mmol/L	NULL
sodium	NULL
citrate/140	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
and	NULL
incubated	NULL
in	NULL
serum-	NULL
and	NULL
growth	NULL
factor-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
fraction	NULL
V	NULL
;	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
for	NULL
2	NULL
to	NULL
4	NULL
hours	NULL
(	NULL
immunoprecipita-tions	NULL
and	NULL
nuclear	NULL
extracts	NULL
)	NULL
or	NULL
in	NULL
growth	NULL
factor-free	NULL
medium	NULL
for	NULL
12	NULL
to	NULL
15	NULL
hours	NULL
(	NULL
mRNA	NULL
preparations	NULL
)	NULL
or	NULL
40	NULL
hours	NULL
(	NULL
apoptosis	NULL
assays	NULL
)	NULL
.	NULL

Stimula-tions	NULL
were	NULL
for	NULL
indicated	NULL
time	NULL
periods	NULL
with	NULL
recombinant	NULL
human	NULL
IL-2	NULL
(	NULL
10	NULL
nmol/L	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
0.01	NULL
to	NULL
100	NULL
U/mL	NULL
)	NULL
,	NULL
or	NULL
IL-3	NULL
(	NULL
10	NULL
%	NULL
WEHI-3B-CM	NULL
)	NULL
.	NULL

Proliferation	NULL
assays	NULL
.	NULL

-	NULL
Conventional	NULL
24-	NULL
to	NULL
48-hour	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
assays	NULL
and	NULL
transient	NULL
proliferation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

''	NULL
For	NULL
the	NULL
transient	NULL
proliferation	NULL
assay	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
20	NULL
ug	NULL
DNA	NULL
at	NULL
300	NULL
V/950	NULL
uF	NULL
and	NULL
incubated	NULL
in	NULL
1	NULL
nmol/L	NULL
IL-2	NULL
for	NULL
24	NULL
hours	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
in	NULL
96-well	NULL
plates	NULL
with	NULL
IL-2	NULL
(	NULL
10	NULL
nmol/L	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
50	NULL
U/mL	NULL
)	NULL
,	NULL
or	NULL
75	NULL
no	NULL
cytokine	NULL
.	NULL

incorporation	NULL
was	NULL
measured	NULL
between	NULL
days	NULL
6	NULL
and	NULL
16	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
averages	NULL
of	NULL
triplicate	NULL
samples	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
10	NULL
nmol/L	NULL
IL-2	NULL
(	NULL
HT-2	NULL
cells	NULL
)	NULL
or	NULL
10	NULL
%	NULL
WEHI-3B-CM	NULL
(	NULL
32D	NULL
and	NULL
371.2	NULL
cells	NULL
)	NULL
.	NULL

Apoptosis	NULL
assays	NULL
.	NULL

-	NULL
Cells	NULL
,	NULL
2	NULL
to	NULL
5	NULL
X	NULL
105	NULL
,	NULL
were	NULL
incubated	NULL
for	NULL
40	NULL
hours	NULL
in	NULL
medium	NULL
without	NULL
cytokines	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
EPO	NULL
(	NULL
50	NULL
U/mL	NULL
)	NULL
or	NULL
IL-2	NULL
(	NULL
10	NULL
nmol/L	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
with	NULL
PBS/2.5	NULL
mmol/L	NULL
CaC1/2	NULL
%	NULL
FBS	NULL
(	NULL
Wash	NULL
Buffer	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
1:1,000	NULL
dilution	NULL
of	NULL
Annexin-GFP	NULL
(	NULL
generously	NULL
provided	NULL
by	NULL
Dr	NULL
Joel	NULL
Ernst	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
)	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
minutes	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
Wash	NULL
Buffer	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
mL	NULL
Wash	NULL
Buffer	NULL
and	NULL
1	NULL
uL	NULL
of	NULL
50	NULL
ug/mL	NULL
Propidium	NULL
Iodide	NULL
(	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
Becton	NULL
Dickinson	NULL
FACScan	NULL
using	NULL
the	NULL
Cellquest	NULL
computer	NULL
program	NULL
.	NULL

MAPK	NULL
assay	NULL
.	NULL

-	NULL
Cells	NULL
,	NULL
10	NULL
to	NULL
20	NULL
X	NULL
10°	NULL
,	NULL
were	NULL
rested	NULL
for	NULL
6	NULL
hours	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokines	NULL
,	NULL
IL-2	NULL
(	NULL
10	NULL
nmol/L	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
50	NULL
U/mL	NULL
)	NULL
,	NULL
or	NULL
murine	NULL
IL-4	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
MAPK	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
an	NULL
MAPK	NULL
assay	NULL
kit	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

In	NULL
short	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
after	NULL
stimulation	NULL
with	NULL
indicated	NULL
cytokines	NULL
.	NULL

Erk1/Erk2	NULL
MAPK	NULL
was	NULL
immunoprecipitated	NULL
using	NULL
an	NULL
antiphospho-MAPK	NULL
anti-body	NULL
.	NULL

Kinase	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
an	NULL
Elkl-glutathione	NULL
S-transferase	NULL
fusion	NULL
protein	NULL
as	NULL
a	NULL
substrate	NULL
with	NULL
subsequent	NULL
immunoblot-ting	NULL
for	NULL
phosphorylated	NULL
Elk1	NULL
.	NULL

Immunoprecipitations	NULL
,	NULL
nuclear	NULL
extracts	NULL
,	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
.	NULL

For	NULL
immunoprecipitations	NULL
of	NULL
JAK	NULL
kinases	NULL
,	NULL
EPOR	NULL
,	NULL
and	NULL
STAT-5	NULL
,	NULL
20	NULL
to	NULL
60	NULL
X	NULL
10	NULL
cells	NULL
were	NULL
rested	NULL
as	NULL
described	NULL
above	NULL
and	NULL
lysed	NULL
in	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
Calbiochem	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
20	NULL
nmol/L	NULL
Tris-HCl	NULL
pH	NULL
8.0	NULL
,	NULL
150	NULL
mmol/L	NULL
NaCl	NULL
,	NULL
50	NULL
mmol/L	NULL
NaF	NULL
,	NULL
100	NULL
mmol/L	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
1	NULL
mmol/L	NULL
phenylmethylsulfony	NULL
]	NULL
fluoride	NULL
,	NULL
10	NULL
ug/mL	NULL
leupeptin	NULL
,	NULL
10	NULL
ug	NULL
aprotinin	NULL
,	NULL
1	NULL
ug/mL	NULL
pepstatin	NULL
A.	NULL
Immunoprecipitations	NULL
were	NULL
performed	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
JAK	NULL
antibodies	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
Inc	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
3	NULL
uL	NULL
of	NULL
a	NULL
C-terminal	NULL
,	NULL
polyclonal	NULL
rabbit	NULL
anti-EPOR	NULL
antisera	NULL
,	NULL
``	NULL
or	NULL
4	NULL
uL	NULL
of	NULL
anti-STAT-5A	NULL
and	NULL
STAT-5B	NULL
antisera**	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Immunoprecipitations	NULL
were	NULL
separated	NULL
on	NULL
8.75	NULL
%	NULL
(	NULL
JAK	NULL
and	NULL
STAT-5	NULL
)	NULL
or	NULL
10	NULL
%	NULL
(	NULL
EPOR	NULL
)	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellu-lose	NULL
.	NULL

Membranes	NULL
were	NULL
probed	NULL
with	NULL
1:1,000	NULL
dilution	NULL
of	NULL
anti-phosphoty-rosine	NULL
4G10	NULL
antibodies	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
Inc	NULL
)	NULL
.	NULL

Membranes	NULL
were	NULL
stripped	NULL
per	NULL
manufacturer	NULL
's	NULL
instructions	NULL
and	NULL
reprobed	NULL
with	NULL
anti-JAK1	NULL
,	NULL
-JAK2	NULL
,	NULL
and	NULL
-JAK3	NULL
antisera	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
with	NULL
anti-STAT-5A	NULL
or	NULL
anti-EPOR	NULL
antisera	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
to	NULL
verify	NULL
equivalent	NULL
loading	NULL
.	NULL

For	NULL
nuclear	NULL
extractions	NULL
,	NULL
30	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
rested	NULL
in	NULL
serum-free	NULL
medium	NULL
containing	NULL
1	NULL
%	NULL
BSA	NULL
for	NULL
2	NULL
to	NULL
4	NULL
hours	NULL
and	NULL
stimulated	NULL
with	NULL
indicated	NULL
cytokines	NULL
for	NULL
15	NULL
minutes	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
and	NULL
nuclear	NULL
extractions	NULL
were	NULL
prepared	NULL
.	NULL

DNA	NULL
binding	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
1	NULL
X	NULL
10°	NULL
cpm	NULL
of	NULL
``	NULL
P-radiolabeled	NULL
FoyRI	NULL
oligonucleotide	NULL
encoding	NULL
an	NULL
STAT	NULL
response	NULL
element	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extract/reaction	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

``	NULL
>	NULL
>	NULL
5	NULL
RNA	NULL
preparation	NULL
and	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
1	NULL
to	NULL
2	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
using	NULL
an	NULL
RNeasy	NULL
kit	NULL
(	NULL
Qiagen	NULL
,	NULL
Valencia	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
quantified	NULL
by	NULL
UV	NULL
spectrophotometry	NULL
.	NULL

Denaturing	NULL
1.4	NULL
%	NULL
agarose	NULL
gels	NULL
were	NULL
run	NULL
with	NULL
10	NULL
to	NULL
15	NULL
ug	NULL
RNA/lane	NULL
,	NULL
blotted	NULL
to	NULL
Zeta	NULL
Probe	NULL
membranes	NULL
(	NULL
BioRad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
hybridized	NULL
with	NULL
c-fos	NULL
,	NULL
bel-2	NULL
,	NULL
and	NULL
GAPD	NULL
probes	NULL
as	NULL
described	NULL
previously	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
The	NULL
435-nucleotide	NULL
be	NULL
!	NULL

-x	NULL
probe	NULL
(	NULL
derived	NULL
from	NULL
the	NULL
5°	NULL
end	NULL
of	NULL
the	NULL
bel-x	NULL
cDNA	NULL
that	NULL
recognizes	NULL
both	NULL
bel-xs	NULL
and	NULL
transcripts	NULL
)	NULL
was	NULL
from	NULL
ATCC.3®	NULL
Somatic	NULL
fusions	NULL
.	NULL

-	NULL
A	NULL
protocol	NULL
to	NULL
create	NULL
fusion	NULL
cell	NULL
lines	NULL
was	NULL
adapted	NULL
from	NULL
Goldsmith	NULL
et	NULL
al	NULL
.	NULL
``	NULL

1.5	NULL
X	NULL
105	NULL
HT-2.EPOR.3	NULL
and	NULL
1.5	NULL
X	NULL
10°	NULL
Ba/F3	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
RPMI	NULL
1640	NULL
,	NULL
mixed	NULL
in	NULL
a	NULL
1:1	NULL
ratio	NULL
(	NULL
or	NULL
3	NULL
X	NULL
105	NULL
of	NULL
either	NULL
cell	NULL
type	NULL
alone	NULL
)	NULL
in	NULL
flat-bottomed	NULL
12-well	NULL
plates	NULL
,	NULL
centrifuged	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
1,200	NULL
rpm	NULL
in	NULL
an	NULL
RT6000B	NULL
table	NULL
top	NULL
centrifuge	NULL
(	NULL
Sorvall	NULL
,	NULL
Newtown	NULL
,	NULL
CT	NULL
)	NULL
,	NULL
and	NULL
depleted	NULL
of	NULL
media	NULL
by	NULL
gentle	NULL
aspiration	NULL
.	NULL

0.3	NULL
mL	NULL
of	NULL
RPMI	NULL
1640	NULL
prewarmed	NULL
to	NULL
37°C	NULL
containing	NULL
various	NULL
concentrations	NULL
(	NULL
40	NULL
%	NULL
to	NULL
65	NULL
%	NULL
)	NULL
of	NULL
polyethylene	NULL
glycol	NULL
(	NULL
PEG	NULL
)	NULL
4000	NULL
(	NULL
ATCC	NULL
)	NULL
diluted	NULL
in	NULL
RPMI	NULL
1640	NULL
was	NULL
overlaid	NULL
slowly	NULL
onto	NULL
the	NULL
cells	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

76	NULL
After	NULL
3	NULL
minutes	NULL
,	NULL
1.5	NULL
mL	NULL
RPMI	NULL
1640	NULL
was	NULL
slowly	NULL
added	NULL
to	NULL
wells	NULL
and	NULL
removed	NULL
by	NULL
gentle	NULL
aspiration	NULL
.	NULL

Wells	NULL
were	NULL
washed	NULL
four	NULL
to	NULL
five	NULL
times	NULL
in	NULL
RPMI	NULL
1640	NULL
and	NULL
resuspended	NULL
in	NULL
complete	NULL
media	NULL
containing	NULL
50	NULL
U/mL	NULL
EPO	NULL
,	NULL
transferred	NULL
to	NULL
fresh	NULL
6-well	NULL
plates	NULL
,	NULL
and	NULL
cultured	NULL
at	NULL
37°C	NULL
.	NULL

25I-EPO	NULL
binding	NULL
assays	NULL
.	NULL

-	NULL
Cells	NULL
were	NULL
washed	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
resuspended	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
6	NULL
X	NULL
10	NULL
``	NULL
cells/mL	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
minutes	NULL
and	NULL
pelleted	NULL
.	NULL

Aliquots	NULL
of	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
in	NULL
triplicate	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
range	NULL
of	NULL
concentrations	NULL
of	NULL
iodinated	NULL
EPO	NULL
at	NULL
4°C	NULL
overnight	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
RPMI/10	NULL
%	NULL
FBS/50	NULL
mmol/L	NULL
HEPES	NULL
,	NULL
pH	NULL
7.2	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
100-fold	NULL
excess	NULL
unlabeled	NULL
EPO	NULL
.	NULL

After	NULL
overnight	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
greater	NULL
than	NULL
90	NULL
%	NULL
viable	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
analysis	NULL
.	NULL

Free	NULL
EPO	NULL
was	NULL
separated	NULL
from	NULL
cell-bound	NULL
EPO	NULL
by	NULL
centrifugation	NULL
through	NULL
100	NULL
%	NULL
FBS	NULL
cushion	NULL
and	NULL
the	NULL
cell	NULL
pellets	NULL
were	NULL
counted	NULL
in	NULL
a	NULL
y	NULL
counter	NULL
.	NULL

The	NULL
data	NULL
were	NULL
plotted	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Scatchard	NULL
.	NULL

Dissociation	NULL
constants	NULL
(	NULL
kd	NULL
)	NULL
and	NULL
cell-surface	NULL
receptor	NULL
numbers	NULL
were	NULL
then	NULL
determined	NULL
through	NULL
Scatchard	NULL
analyses	NULL
.	NULL

RESULTS	NULL
The	NULL
EPOR	NULL
inhibits	NULL
apoptosis	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
function	NULL
of	NULL
the	NULL
EPOR	NULL
in	NULL
an	NULL
IL-2-responsive	NULL
cell	NULL
,	NULL
stable	NULL
HT-2	NULL
cell	NULL
lines	NULL
were	NULL
generated	NULL
that	NULL
expressed	NULL
the	NULL
EPOR	NULL
(	NULL
designated	NULL
HT-2.EPOR.3*	NULL
)	NULL
,	NULL
and	NULL
mRNA	NULL
expression	NULL
was	NULL
confirmed	NULL
by	NULL
Northern	NULL
blotting	NULL
(	NULL
Fig	NULL
1A	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
EPOR	NULL
serves	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
in	NULL
erythroid	NULL
progenitors	NULL
,	NULL
``	NULL
and	NULL
several	NULL
cytokines	NULL
inhibit	NULL
apoptosis	NULL
in	NULL
HT-2	NULL
cells.4	NULL
Therefore	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
EPOR	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
induced	NULL
by	NULL
IL-2	NULL
withdrawal	NULL
by	NULL
incubating	NULL
cells	NULL
for	NULL
40	NULL
hours	NULL
without	NULL
cytokine	NULL
,	NULL
with	NULL
IL-2	NULL
or	NULL
with	NULL
EPO	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
stained	NULL
with	NULL
propidium	NULL
iodide	NULL
(	NULL
PI	NULL
)	NULL
and	NULL
Annexin	NULL
V	NULL
coupled	NULL
to	NULL
green	NULL
fluorescent	NULL
protein	NULL
(	NULL
Annexin-GFP	NULL
)	NULL
*	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

First	NULL
,	NULL
PI	NULL
staining	NULL
was	NULL
used	NULL
to	NULL
measure	NULL
cell	NULL
death	NULL
.	NULL

Incubation	NULL
of	NULL
HT-2	NULL
or	NULL
HT-2.EPOR.3	NULL
cells	NULL
without	NULL
cytokines	NULL
resulted	NULL
in	NULL
significant	NULL
cell	NULL
death	NULL
,	NULL
because	NULL
only	NULL
25.2	NULL
%	NULL
or	NULL
14.2	NULL
%	NULL
of	NULL
HT-2	NULL
or	NULL
HT-2.EPOR.3	NULL
cells	NULL
excluded	NULL
PI	NULL
,	NULL
respec-tively	NULL
,	NULL
in	NULL
a	NULL
typical	NULL
experiment	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

The	NULL
slight	NULL
differences	NULL
in	NULL
cell	NULL
death	NULL
among	NULL
cell	NULL
lines	NULL
represent	NULL
experimental	NULL
variation	NULL
,	NULL
because	NULL
they	NULL
were	NULL
not	NULL
consistently	NULL
observed	NULL
over	NULL
multiple	NULL
experiments	NULL
.	NULL

However	NULL
,	NULL
signaling	NULL
through	NULL
the	NULL
EPOR	NULL
dramatically	NULL
and	NULL
reproducibly	NULL
protected	NULL
HT-2.EPOR.3	NULL
cells	NULL
from	NULL
death	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EPO	NULL
,	NULL
as	NULL
62.1	NULL
%	NULL
of	NULL
cells	NULL
excluded	NULL
PI	NULL
,	NULL
compared	NULL
with	NULL
27.3	NULL
%	NULL
of	NULL
the	NULL
parental	NULL
HT-2	NULL
cells	NULL
lacking	NULL
the	NULL
EPOR	NULL
.	NULL

Finally	NULL
,	NULL
IL-2	NULL
signaling	NULL
prevented	NULL
cell	NULL
death	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
(	NULL
94.8	NULL
%	NULL
of	NULL
HT-2	NULL
and	NULL
83.2	NULL
%	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
were	NULL
PI-negative	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
stimulation	NULL
by	NULL
EPO	NULL
conferred	NULL
cell	NULL
survival	NULL
on	NULL
EPOR-expressing	NULL
HT-2	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
protection	NULL
was	NULL
not	NULL
as	NULL
complete	NULL
as	NULL
that	NULL
observed	NULL
when	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
IL-2	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
EPOR	NULL
was	NULL
inhibiting	NULL
apoptosis	NULL
per	NULL
se	NULL
,	NULL
the	NULL
Pl-negative	NULL
populations	NULL
were	NULL
examined	NULL
for	NULL
staining	NULL
by	NULL
Annexin-GFP	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
phosphatidylserine	NULL
and	NULL
serves	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
apoptosis	NULL
(	NULL
Fig	NULL
1B	NULL
)	NULL
.	NULL

Virtually	NULL
all	NULL
HT-2	NULL
and	NULL
HT-2.EPOR.3	NULL
cells	NULL
incubated	NULL
without	NULL
cytokine	NULL
that	NULL
were	NULL
still	NULL
alive	NULL
(	NULL
ie	NULL
,	NULL
Pl-negative	NULL
)	NULL
bound	NULL
to	NULL
Annexin-GFP	NULL
(	NULL
96.7	NULL
%	NULL
of	NULL
HT-2	NULL
and	NULL
92.2	NULL
%	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
they	NULL
were	NULL
apoptotic	NULL
.	NULL

Similarly	NULL
,	NULL
93.1	NULL
%	NULL
of	NULL
PI-negative	NULL
HT-2	NULL
cells	NULL
(	NULL
that	NULL
did	NULL
not	NULL
express	NULL
the	NULL
EPOR	NULL
)	NULL
were	NULL
Annexin-GFP-positive	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EPO	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
entire	NULL
culture	NULL
was	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
HT-2.EPOR.3	NULL
cells	NULL
showed	NULL
signifi-cant	NULL
,	NULL
EPO-dependent	NULL
protection	NULL
from	NULL
apoptosis	NULL
,	NULL
because	NULL
only	NULL
10.2	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
stained	NULL
positively	NULL
with	NULL
Annexin-GFP	NULL
in	NULL
the	NULL
GAFFEN	NULL
ET	NULL
AL	NULL
presence	NULL
of	NULL
EPO	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
IL-2	NULL
treatment	NULL
strongly	NULL
protected	NULL
both	NULL
cell	NULL
lines	NULL
from	NULL
apoptosis	NULL
(	NULL
6.2	NULL
%	NULL
of	NULL
HT-2	NULL
and	NULL
3.7	NULL
%	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
were	NULL
Annexin-GFP-positive	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
anti-apoptotic	NULL
effect	NULL
of	NULL
EPO	NULL
occurred	NULL
in	NULL
a	NULL
dose-responsive	NULL
fashion	NULL
,	NULL
with	NULL
detectable	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
and	NULL
a	NULL
corresponding	NULL
increase	NULL
in	NULL
percentage	NULL
of	NULL
live	NULL
cells	NULL
evident	NULL
at	NULL
concentrations	NULL
of	NULL
EPO	NULL
as	NULL
low	NULL
as	NULL
0.2	NULL
U/mL	NULL
(	NULL
Fig	NULL
1C	NULL
)	NULL
.	NULL

These	NULL
data	NULL
show	NULL
that	NULL
the	NULL
EPOR	NULL
prevents	NULL
HT-2.EPOR.3	NULL
cell	NULL
death	NULL
upon	NULL
cytokine	NULL
withdrawal	NULL
by	NULL
delivering	NULL
a	NULL
potent	NULL
anti-apoptotic	NULL
signal	NULL
.	NULL

EPOR	NULL
alone	NULL
fails	NULL
to	NULL
support	NULL
proliferation	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
EPOR	NULL
to	NULL
mediate	NULL
growth	NULL
signaling	NULL
in	NULL
the	NULL
HT-2	NULL
cell	NULL
background	NULL
was	NULL
evaluated	NULL
by	NULL
measuring	NULL
incorporation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
in	NULL
cells	NULL
incubated	NULL
in	NULL
either	NULL
IL-2	NULL
or	NULL
EPO	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
HT-2	NULL
cells	NULL
expressing	NULL
chimeric	NULL
receptors	NULL
in	NULL
which	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
EPOR	NULL
was	NULL
replaced	NULL
with	NULL
the	NULL
cytoplasmic	NULL
tails	NULL
of	NULL
either	NULL
the	NULL
IL-2RfB	NULL
or	NULL
yc	NULL
chains	NULL
(	NULL
EPOR®	NULL
and	NULL
EPOy	NULL
)	NULL
responded	NULL
vigorously	NULL
to	NULL
EPO	NULL
after	NULL
24	NULL
hours	NULL
of	NULL
stimulation	NULL
(	NULL
Fig	NULL
In	NULL
contrast	NULL
,	NULL
parental	NULL
HT-2	NULL
cells	NULL
failed	NULL
to	NULL
incorporate	NULL
significant	NULL
levels	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
.	NULL

Strikingly	NULL
,	NULL
HT-2.EPOR.3	NULL
cells	NULL
did	NULL
not	NULL
incorporate	NULL
high	NULL
levels	NULL
of	NULL
although	NULL
there	NULL
was	NULL
a	NULL
small	NULL
but	NULL
reproducible	NULL
signal	NULL
that	NULL
peaked	NULL
at	NULL
approximately	NULL
8	NULL
%	NULL
of	NULL
IL-2	NULL
levels	NULL
in	NULL
very	NULL
high	NULL
doses	NULL
of	NULL
EPO	NULL
(	NULL
Fig	NULL
2A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
EPO	NULL
failed	NULL
entirely	NULL
to	NULL
sustain	NULL
growth	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
EPO	NULL
triggers	NULL
a	NULL
minimal	NULL
but	NULL
transient	NULL
proliferative	NULL
response	NULL
in	NULL
HT-2	NULL
cells	NULL
that	NULL
is	NULL
greatly	NULL
reduced	NULL
compared	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
IL-2	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
EPOR	NULL
cDNA	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
encodes	NULL
a	NULL
functional	NULL
receptor	NULL
that	NULL
supports	NULL
cell	NULL
growth	NULL
in	NULL
an	NULL
permissive	NULL
cellular	NULL
background	NULL
,	NULL
the	NULL
EPOR	NULL
was	NULL
expressed	NULL
stably	NULL
in	NULL
the	NULL
IL-3-dependent	NULL
myeloid	NULL
cell	NULL
line	NULL
,	NULL
32D.4	NULL
In	NULL
contrast	NULL
to	NULL
HT-2	NULL
cells	NULL
,	NULL
32D.EPOR	NULL
cells	NULL
exhibited	NULL
a	NULL
vigorous	NULL
proliferative	NULL
dose	NULL
response	NULL
to	NULL
EPO	NULL
,	NULL
while	NULL
the	NULL
parental	NULL
32D	NULL
line	NULL
lacking	NULL
the	NULL
EPOR	NULL
failed	NULL
to	NULL
proliferate	NULL
(	NULL
Fig	NULL
2B	NULL
)	NULL
.	NULL

Together	NULL
with	NULL
the	NULL
anti-apoptotic	NULL
effect	NULL
described	NULL
earlier	NULL
,	NULL
these	NULL
data	NULL
show	NULL
that	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
and	NULL
induction	NULL
of	NULL
proliferation	NULL
are	NULL
separable	NULL
signaling	NULL
events	NULL
.	NULL

Finally	NULL
,	NULL
to	NULL
verify	NULL
that	NULL
the	NULL
HT-2.EPOR.3	NULL
cells	NULL
express	NULL
potentially	NULL
functional	NULL
EPO	NULL
receptors	NULL
,	NULL
the	NULL
EPORB	NULL
chimeric	NULL
receptor	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
HT-2.EPOR.3	NULL
cells	NULL
,	NULL
and	NULL
[	NULL
*H	NULL
]	NULL
thy-midine	NULL
incorporation	NULL
was	NULL
measured	NULL
over	NULL
a	NULL
16-day	NULL
period	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
,	NULL
although	NULL
the	NULL
EPORB	NULL
receptor	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
support	NULL
growth	NULL
signaling	NULL
,	NULL
it	NULL
can	NULL
signal	NULL
proliferation	NULL
when	NULL
paired	NULL
with	NULL
either	NULL
the	NULL
EPOy	NULL
chimera	NULL
or	NULL
with	NULL
a	NULL
truncated	NULL
EPOR	NULL
retaining	NULL
the	NULL
JAK2-binding	NULL
domain	NULL
[	NULL
EPOR	NULL
(	NULL
1-321	NULL
)	NULL
°	NULL
``	NULL
]	NULL
.	NULL

EPOR	NULL
also	NULL
exhibited	NULL
a	NULL
characteristically	NULL
potent	NULL
proliferative	NULL
response	NULL
to	NULL
EPO	NULL
when	NULL
paired	NULL
with	NULL
the	NULL
full-length	NULL
EPOR	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
,	NULL
whereas	NULL
a	NULL
control	NULL
vector	NULL
alone	NULL
failed	NULL
to	NULL
induce	NULL
[	NULL
*HJthymidine	NULL
incorporation	NULL
(	NULL
Fig	NULL
2C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
experiments	NULL
show	NULL
that	NULL
the	NULL
HT-2	NULL
cell	NULL
line	NULL
is	NULL
restricted	NULL
in	NULL
its	NULL
ability	NULL
to	NULL
respond	NULL
to	NULL
cytokines	NULL
:	NULL
while	NULL
the	NULL
IL-2R	NULL
(	NULL
or	NULL
EPOB/	NULL
EPOy	NULL
chimeras	NULL
)	NULL
delivers	NULL
effective	NULL
growth	NULL
signals	NULL
to	NULL
these	NULL
cells	NULL
,	NULL
the	NULL
EPOR	NULL
is	NULL
insufficient	NULL
to	NULL
promote	NULL
proliferation	NULL
or	NULL
long-term	NULL
survival	NULL
in	NULL
EPO	NULL
.	NULL

The	NULL
EPOR	NULL
fails	NULL
to	NULL
activate	NULL
STAT	NULL
factors	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

A	NULL
dominant	NULL
pathway	NULL
activated	NULL
by	NULL
cytokine	NULL
receptors	NULL
is	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
,	NULL
and	NULL
EPOR-derived	NULL
proliferation	NULL
signaling	NULL
has	NULL
been	NULL
linked	NULL
to	NULL
JAK2	NULL
and	NULL
STAT-5	NULL
activation	NULL
in	NULL
some	NULL
settings	NULL
.	NULL

'*'52	NULL
%	NULL
2	NULL
'	NULL
Therefore	NULL
,	NULL
to	NULL
determine	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

ADDITIONAL	NULL
FACTOR	NULL
NEEDED	NULL
FOR	NULL
EPOR	NULL
SIGNALING	NULL
77	NULL
A	NULL
Q	NULL
?	NULL

B	NULL
O	NULL
HT-2	NULL
Cells	NULL
&	NULL
None	NULL
IL-2	NULL
Ero	NULL
300	NULL
300	NULL
300	NULL
w	NULL
q	NULL
;	NULL
25.2	NULL
%	NULL
94.8	NULL
%	NULL
27.3	NULL
%	NULL
&	NULL
'	NULL
&	NULL
'	NULL
2404	NULL
2401	NULL
2401	NULL
Q	NULL
“	NULL
Q	NULL
“	NULL
1801	NULL
1801	NULL
180	NULL
Propidium	NULL
1201	NULL
1201	NULL
1201	NULL
lodide	NULL
C	NULL
F	NULL
may	NULL
Ae	NULL
S	NULL
ot	NULL
.	NULL

r	NULL
o	NULL
-	NULL
:	NULL
o+	NULL
g	NULL
10°	NULL
o	NULL
'	NULL
10	NULL
10°	NULL
10°	NULL
10°	NULL
y	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10	NULL
10°	NULL
10°	NULL
10°	NULL
6	NULL
``	NULL
|	NULL
t	NULL
t	NULL
G	NULL
200	NULL
200	NULL
300	NULL
O	NULL
1601	NULL
2401	NULL
2404	NULL
96.7	NULL
%	NULL
6.2	NULL
%	NULL
93.1	NULL
%	NULL
GFP-fff	NULL
1201	NULL
{	NULL
--	NULL
-	NULL
1801	NULL
-*-	NULL
1801	NULL
[	NULL
--	NULL
*	NULL
,	NULL
.	NULL

Annexin	NULL
V	NULL
>	NULL
801	NULL
1201	NULL
1201	NULL
401	NULL
ﬂ	NULL
604	NULL
60	NULL
1	NULL
2	NULL
o	NULL
s	NULL
r	NULL
r	NULL
0	NULL
re	NULL
m	NULL
usan	NULL
e	NULL
m	NULL
r	NULL
10°	NULL
10	NULL
10°	NULL
10°	NULL
10	NULL
%	NULL
10°	NULL
10	NULL
'	NULL
10°	NULL
10°	NULL
10	NULL
%	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
HT-2.EPOR.3	NULL
Cells	NULL
C	NULL
None	NULL
IL-2	NULL
EPO	NULL
300	NULL
300	NULL
300	NULL
a	NULL
'	NULL
``	NULL
14.2	NULL
%	NULL
83.2	NULL
%	NULL
621	NULL
%	NULL
T	NULL
2404	NULL
2404	NULL
2404	NULL
I	NULL
g	NULL
ha	NULL
:	NULL
©	NULL
180	NULL
1804	NULL
1804	NULL
Propidium	NULL
B	NULL
so	NULL
1201	NULL
1204	NULL
1201	NULL
lodide	NULL
5	NULL
5	NULL
60	NULL
604	NULL
UNA	NULL
60	NULL
&	NULL
ao	NULL
#	NULL
(	NULL
LN	NULL
o	NULL
L/	NULL
&	NULL
3	NULL
o	NULL
Wirt	NULL
n	NULL
?	NULL

Hes	NULL
a	NULL
o	NULL
Tam	NULL
:	NULL
tn	NULL
?	NULL

ns	NULL
4	NULL
400	NULL
1	NULL
n	NULL
ns	NULL
a	NULL
a	NULL
3	NULL
1	NULL
0	NULL
10	NULL
10	NULL
10°	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10°	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10	NULL
a	NULL
0	NULL
*	NULL
a	NULL
20	NULL
-=	NULL
o	NULL
B	NULL
200	NULL
300	NULL
300	NULL
$	NULL
O	NULL
``	NULL
o	NULL
160	NULL
2404	NULL
2404	NULL
0	NULL
02	NULL
2	NULL
20	NULL
100	NULL
IL-2	NULL
W	NULL
1204	NULL
1804	NULL
1804	NULL
gFP	NULL
'	NULL
in	NULL
V	NULL
92.2	NULL
%	NULL
3.7	NULL
%	NULL
10.2	NULL
%	NULL
nnexin	NULL
C	NULL
80	NULL
801	NULL
--	NULL
-	NULL
1204	NULL
[	NULL
--	NULL
-	NULL
1204	NULL
E	NULL
401	NULL
601	NULL
60	NULL
&	NULL
60	NULL
3	NULL
0	NULL
e	NULL
.	NULL

r	NULL
0	NULL
e	NULL
m	NULL
r	NULL
0	NULL
e	NULL
m	NULL
T	NULL
3	NULL
10°	NULL
_	NULL
do	NULL
'	NULL
10°	NULL
0	NULL
qo	NULL
0	NULL
aot	NULL
ao	NULL
_	NULL
do	NULL
'	NULL
10h	NULL
0	NULL
ao	NULL
_	NULL
aot	NULL
ao	NULL
0	NULL
aot	NULL
_	NULL
aot	NULL
_	NULL
ao	NULL
_	NULL
ao	NULL
Fi	NULL
Fluorescence	NULL
;	NULL
40	NULL
a	NULL
a	NULL
c	NULL
Q	NULL
20	NULL
3	NULL
o	NULL
.	NULL

B	NULL
*	NULL
o	NULL
0	NULL
Or	NULL
20	NULL
20	NULL
100	NULL
IL-2	NULL
EPO	NULL
(	NULL
U/m1	NULL
)	NULL
Fig	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HT-2.EPOR	NULL
cells	NULL
express	NULL
EPOR	NULL
mRNA	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
cytoplasmic	NULL
RNA	NULL
from	NULL
HT-2.EPOR.3	NULL
and	NULL
HT-2	NULL
cells	NULL
was	NULL
separated	NULL
by	NULL
denaturing	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
,	NULL
transferred	NULL
to	NULL
Zeta	NULL
Probe	NULL
membranes	NULL
and	NULL
probed	NULL
with	NULL
a	NULL
**P-labeled	NULL
1.2-kb	NULL
DNA	NULL
fragment	NULL
corresponding	NULL
to	NULL
the	NULL
EPOR	NULL
extracellular	NULL
domain	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
The	NULL
EPOR	NULL
protects	NULL
HT-2	NULL
cells	NULL
from	NULL
cell	NULL
death	NULL
and	NULL
apoptosis	NULL
.	NULL

HT-2	NULL
and	NULL
HT-2.EPOR.3	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
40	NULL
hours	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
None	NULL
)	NULL
,	NULL
20	NULL
U/mL	NULL
or	NULL
indicated	NULL
doses	NULL
of	NULL
EPO	NULL
(	NULL
Epo	NULL
)	NULL
,	NULL
or	NULL
10	NULL
nmol/L	NULL
IL-2	NULL
(	NULL
IL-2	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
costained	NULL
with	NULL
PI	NULL
and	NULL
Annexin-GFP	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

signaling	NULL
block	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
EPO	NULL
to	NULL
activate	NULL
JAK2	NULL
and	NULL
STAT-5	NULL
was	NULL
examined	NULL
.	NULL

HT-2.EPOR.3	NULL
cells	NULL
were	NULL
starved	NULL
of	NULL
IL-2	NULL
and	NULL
incubated	NULL
for	NULL
10	NULL
minutes	NULL
with	NULL
no	NULL
cytokine	NULL
,	NULL
EPO	NULL
,	NULL
or	NULL
IL-2	NULL
(	NULL
in	NULL
these	NULL
and	NULL
subsequent	NULL
experiments	NULL
,	NULL
supra-physiological	NULL
doses	NULL
of	NULL
EPO	NULL
were	NULL
used	NULL
to	NULL
achieve	NULL
maximal	NULL
stimulation	NULL
of	NULL
the	NULL
EPO	NULL
receptors	NULL
expressed	NULL
on	NULL
target	NULL
cells	NULL
)	NULL
.	NULL

Cellular	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
antibodies	NULL
to	NULL
JAK	NULL
1	NULL
,	NULL
JAK2	NULL
,	NULL
or	NULL
JAK3	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
(	NULL
Fig	NULL
3A	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
when	NULL
HT-2.EPOR.3	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
IL-2	NULL
,	NULL
JAK1	NULL
and	NULL
JAK3	NULL
,	NULL
but	NULL
not	NULL
JAK2	NULL
,	NULL
became	NULL
phosphory-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Relative	NULL
°H-Thymidine	NULL
Incorporation	NULL
(	NULL
%	NULL
of	NULL
IL-2	NULL
)	NULL
>	NULL
0	NULL
T	NULL
i	NULL
i	NULL
T	NULL
i	NULL
i	NULL
0	NULL
01	NULL
A	NULL
1	NULL
10	NULL
-	NULL
100	NULL
1000	NULL
EPO	NULL
(	NULL
U/m	NULL
!	NULL
)	NULL

a	NULL
=	NULL
!	NULL

2007	NULL
6	NULL
x	NULL
5	NULL
150	NULL
C	NULL
0	NULL
o	NULL
8	NULL
A	NULL
g	NULL
100	NULL
0	NULL
.C	NULL
C	NULL
E	NULL
507	NULL
P=	NULL
<	NULL
|	NULL
ju	NULL
m	NULL
4	NULL
&	NULL
p	NULL
m	NULL
m	NULL
m.	NULL
m	NULL
-g	NULL
0	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
-i	NULL
tc	NULL
0	NULL
_	NULL
.01	NULL
A	NULL
1	NULL
10	NULL
-	NULL
100	NULL
1000	NULL
@	NULL
cC	NULL
EPO	NULL
(	NULL
U/m	NULL
!	NULL
)	NULL

lated	NULL
on	NULL
tyrosine	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
the	NULL
same	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
EPO	NULL
,	NULL
JAK2	NULL
alone	NULL
was	NULL
found	NULL
to	NULL
be	NULL
phosphorylated	NULL
(	NULL
Fig	NULL
3A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
JAK2	NULL
activation	NULL
is	NULL
clearly	NULL
not	NULL
the	NULL
block	NULL
to	NULL
EPO	NULL
signaling	NULL
in	NULL
this	NULL
context	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
EPO	NULL
to	NULL
activate	NULL
STAT-5	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
starved	NULL
of	NULL
cytokine	NULL
and	NULL
stimulated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
EPO	NULL
,	NULL
and	NULL
nuclear	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
subjected	NULL
to	NULL
EMSA	NULL
using	NULL
a	NULL
generic	NULL
STAT-response	NULL
element	NULL
derived	NULL
from	NULL
the	NULL
FoyRI	NULL
gene	NULL
that	NULL
recognizes	NULL
a	NULL
variety	NULL
of	NULL
STAT	NULL
factors	NULL
.	NULL
``	NULL

''	NULL
As	NULL
previously	NULL
reported	NULL
,	NULL
``	NULL
°	NULL
IL-2	NULL
stimulation	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
resulted	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
specific	NULL
retarded	NULL
nucleoprotein	NULL
complex	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
that	NULL
could	NULL
be	NULL
supershifted	NULL
with	NULL
antibodies	NULL
to	NULL
STAT-5A	NULL
and	NULL
STAT-5B	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
failed	NULL
to	NULL
cause	NULL
significant	NULL
retardation	NULL
of	NULL
the	NULL
probe	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
STAT-response	NULL
element	NULL
used	NULL
in	NULL
this	NULL
GAFFEN	NULL
ET	NULL
AL	NULL
C	NULL
120000	NULL
;	NULL
e	NULL
€	NULL
&	NULL
100000	NULL
[	NULL
=	NULL
0	NULL
T	NULL
80000	NULL
o	NULL
[	NULL
=	NULL
8	NULL
600001	NULL
£	NULL
2	NULL
he	NULL
]	NULL
40000	NULL
€	NULL
2	NULL
i	NULL
20000	NULL
#	NULL
|	NULL
-*	NULL
0	NULL
T	NULL
T	NULL
T	NULL
T	NULL
p	NULL
-	NULL
1	NULL
4	NULL
6	NULL
8	NULL
10	NULL
_	NULL
12	NULL
14	NULL
16	NULL
18	NULL
Day	NULL
Fig	NULL
2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
EPOR	NULL
fails	NULL
to	NULL
support	NULL
proliferation	NULL
signaling	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

HT-2	NULL
[	NULL
)	NULL
,	NULL
HT-2.EPOR.3	NULL
(	NULL
#	NULL
)	NULL
,	NULL
and	NULL
HT-2EPOBy	NULL
(	NULL
0	NULL
)	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
no	NULL
cytokine	NULL
,	NULL
various	NULL
doses	NULL
of	NULL
EPO	NULL
,	NULL
or	NULL
10	NULL
nmol/L	NULL
IL-2	NULL
and	NULL
incorporation	NULL
of	NULL
[	NULL
``	NULL
H|thymidine	NULL
was	NULL
measured	NULL
at	NULL
48	NULL
hours	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
percent	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
relative	NULL
to	NULL
IL-2	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
EPOR	NULL
supports	NULL
proliferation	NULL
signaling	NULL
in	NULL
32D	NULL
cells	NULL
.	NULL

32D	NULL
(	NULL
[	NULL
-	NULL
)	NULL
and	NULL
32D.EPOR	NULL
(	NULL
®	NULL
)	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
no	NULL
cytokine	NULL
,	NULL
various	NULL
doses	NULL
of	NULL
EPO	NULL
,	NULL
or	NULL
10	NULL
%	NULL
WEHI-CM	NULL
(	NULL
IL-3	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
percent	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
relative	NULL
to	NULL
IL-3	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
EPOR	NULL
can	NULL
pair	NULL
with	NULL
EPORB	NULL
to	NULL
support	NULL
EPO-dependent	NULL
proliferation	NULL
signaling	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

HT-2.EPOR.3	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
mg	NULL
of	NULL
pCMV4	NULL
vector	NULL
with	NULL
no	NULL
insert	NULL
(	NULL
control	NULL
,	NULL
@	NULL
)	NULL
or	NULL
pCMV4.EPORB	NULL
(	NULL
EPOB	NULL
,	NULL
C	NULL
)	NULL
)	NULL
and	NULL
[	NULL
°HIJthymidine	NULL
incorporation	NULL
measured	NULL
on	NULL
days	NULL
6-16	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

experiment	NULL
can	NULL
also	NULL
bind	NULL
STAT-1	NULL
and	NULL
STAT-3,4	NULL
which	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
the	NULL
EPOR*	NULL
``	NULL
;	NULL
therefore	NULL
,	NULL
the	NULL
EPOR	NULL
fails	NULL
to	NULL
induce	NULL
any	NULL
known	NULL
STAT	NULL
factors	NULL
in	NULL
this	NULL
cellular	NULL
context	NULL
.	NULL

Furthermore	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
371.2.EPOR	NULL
cells	NULL
(	NULL
derived	NULL
from	NULL
32D	NULL
cells	NULL
``	NULL
``	NULL
)	NULL
induced	NULL
STAT-5	NULL
,	NULL
verifying	NULL
that	NULL
the	NULL
EPOR	NULL
cDNA	NULL
is	NULL
fully	NULL
functional	NULL
in	NULL
permissive	NULL
cells	NULL
(	NULL
Fig	NULL
3B	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Because	NULL
STAT-5	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
the	NULL
EPOR	NULL
,	NULL
we	NULL
next	NULL
examined	NULL
whether	NULL
STAT-5	NULL
was	NULL
inducibly	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
after	NULL
receptor	NULL
stimulation	NULL
.	NULL

HT-2.EPOR	NULL
cells	NULL
were	NULL
starved	NULL
of	NULL
IL-2	NULL
and	NULL
incubated	NULL
with	NULL
no	NULL
cytokine	NULL
,	NULL
EPO	NULL
,	NULL
or	NULL
IL-2	NULL
for	NULL
15	NULL
minutes	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
antibodies	NULL
to	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
,	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
.	NULL

Although	NULL
IL-2	NULL
induced	NULL
strong	NULL
phosphorylation	NULL
of	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
in	NULL
HT-2	NULL
cells	NULL
,	NULL
EPO	NULL
failed	NULL
to	NULL
induce	NULL
detectable	NULL
phosphorylation	NULL
.	NULL

From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

ADDITIONAL	NULL
FACTOR	NULL
NEEDED	NULL
FOR	NULL
EPOR	NULL
SIGNALING	NULL
79	NULL
A	NULL
-	NULL
IP	NULL
:	NULL
JAK	NULL
!	NULL

JAK2	NULL
JAK3	NULL
C	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
2	NULL
206	NULL
-	NULL
®	NULL
Anti-P-Tyr	NULL
137	NULL
102	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
s	NULL
900	NULL
Anti-STATSA/B	NULL
10	NULL
2003	NULL
B	NULL
-	NULL
HT-2	NULL
.	NULL

371.2	NULL
.	NULL

EPOR.3	NULL
EPOR	NULL
U	NULL
E	NULL
2	NULL
2	NULL
2	NULL
U	NULL
E	NULL
3	NULL
;	NULL
_	NULL
D	NULL
3	NULL
%	NULL
0	NULL
o	NULL
o	NULL
M.	NULL
**	NULL
,	NULL
Ades	NULL
©	NULL
5	NULL
9	NULL
e	NULL
§	NULL
--	NULL
u	NULL
G	NULL
-	NULL
u	NULL
o	NULL
N	NULL
o	NULL
«	NULL
A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
|	NULL
:	NULL
|—	NULL
:	NULL
D	NULL
|	NULL
:	NULL
|_	NULL
:	NULL
s	NULL
©	NULL
.0	NULL
U	NULL
E	NULL
U	NULL
E	NULL
U	NULL
E	NULL
U	NULL
E	NULL
es	NULL
$	NULL
220	NULL
--	NULL
UV	NULL
W	NULL
:	NULL
anti-P-Tyr	NULL
of	NULL
}	NULL
?	NULL

10	NULL
2	NULL
30	NULL
4	NULL
5	NULL
60	NULL
7	NULL
8	NULL
&	NULL
``	NULL
IP	NULL
:	NULL
-	NULL
Anti-EPOR	NULL
Pre-immune	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
EPO	NULL
signaling	NULL
mediates	NULL
phosphorylation	NULL
of	NULL
JAK2	NULL
and	NULL
the	NULL
EPOR	NULL
but	NULL
not	NULL
STAT-5	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HT-2.EPOR.3	NULL
cells	NULL
were	NULL
rested	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
50	NULL
U/mL	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
,	NULL
or	NULL
10	NULL
nmol/L	NULL
IL-2	NULL
(	NULL
2	NULL
)	NULL
and	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
5	NULL
g	NULL
of	NULL
antibodies	NULL
to	NULL
JAK1	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
3	NULL
)	NULL
,	NULL
JAK2	NULL
(	NULL
lanes	NULL
4	NULL
through	NULL
6	NULL
)	NULL
,	NULL
or	NULL
JAK3	NULL
(	NULL
lanes	NULL
7	NULL
through	NULL
9	NULL
)	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
separated	NULL
on	NULL
8.75	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
.	NULL

Migration	NULL
of	NULL
molecular-weight	NULL
markers	NULL
is	NULL
indicated	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
phosphorylated	NULL
JAK3	NULL
in	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
is	NULL
probably	NULL
background	NULL
phosphorylation	NULL
resulting	NULL
from	NULL
incomplete	NULL
IL-2	NULL
deprivation	NULL
of	NULL
the	NULL
cells	NULL
before	NULL
restimulation	NULL
with	NULL
the	NULL
indicated	NULL
cytokines	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HT-2.EPOR.3	NULL
and	NULL
371.2	NULL
cells	NULL
were	NULL
rested	NULL
and	NULL
stimulated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
50	NULL
U/mL	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
,	NULL
10	NULL
nmol/L	NULL
IL-2	NULL
(	NULL
2	NULL
)	NULL
,	NULL
or	NULL
10	NULL
%	NULL
WEHI-CM	NULL
(	NULL
IL-3	NULL
)	NULL
(	NULL
3	NULL
)	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
nuclear	NULL
extracts	NULL
and	NULL
a	NULL
``	NULL
P-labeled	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
FeyRI	NULL
STAT-response	NULL
element	NULL
.	NULL
``	NULL

''	NULL
Supershifts	NULL
were	NULL
performed	NULL
by	NULL
preincubating	NULL
nuclear	NULL
extracts	NULL
with	NULL
anti-STAT-5A	NULL
and	NULL
-5B	NULL
antisera	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
preimmune	NULL
rabbit	NULL
sera	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
for	NULL
45	NULL
minutes	NULL
before	NULL
the	NULL
EMSA	NULL
reaction	NULL
.	NULL

(	NULL
C	NULL
)	NULL
HT-2.EPOR.3	NULL
cells	NULL
were	NULL
rested	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
,	NULL
or	NULL
IL-2	NULL
(	NULL
2	NULL
)	NULL
and	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
antibodies	NULL
to	NULL
STAT-5A	NULL
and	NULL
-5B	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
separated	NULL
on	NULL
8.75	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-STAT-5A	NULL
and	NULL
-5B	NULL
antibodies	NULL
.	NULL

(	NULL
D	NULL
)	NULL
5	NULL
x	NULL
10°	NULL
HT-2.EPOR.3	NULL
cells/	NULL
sample	NULL
or	NULL
2	NULL
x	NULL
10°	NULL
371.2.EPOR	NULL
cells/sample	NULL
were	NULL
rested	NULL
and	NULL
incubated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
or	NULL
50	NULL
U/mL	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
and	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-EPOR	NULL
antibodies	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
separated	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
initial	NULL
step	NULL
of	NULL
STAT-5	NULL
activation	NULL
by	NULL
phosphorylation	NULL
provide	NULL
docking	NULL
sites	NULL
for	NULL
signaling	NULL
intermediates	NULL
such	NULL
as	NULL
on	NULL
tyrosine	NULL
fails	NULL
to	NULL
occur	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
.	NULL

STAT-5	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
EPOR	NULL
was	NULL
phosphorylated	NULL
This	NULL
lack	NULL
of	NULL
STAT-5	NULL
activation	NULL
could	NULL
be	NULL
explained	NULL
if	NULL
the	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
EPO	NULL
for	NULL
25	NULL
EPOR	NULL
itself	NULL
were	NULL
not	NULL
phosphorylated	NULL
after	NULL
receptor	NULL
engagement	NULL
minutes	NULL
,	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-and	NULL
JAK2	NULL
activation	NULL
,	NULL
because	NULL
it	NULL
would	NULL
then	NULL
be	NULL
unable	NULL
to	NULL
EPOR	NULL
antibodies	NULL
.	NULL
``	NULL

Lysates	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

80	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
(	NULL
Fig	NULL
3D	NULL
)	NULL
.	NULL

In	NULL
both	NULL
HT-2EPOR.3	NULL
cells	NULL
and	NULL
control	NULL
371.2.EPOR	NULL
cells	NULL
,	NULL
EPO	NULL
stimulation	NULL
resulted	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
EPOR	NULL
(	NULL
Fig	NULL
3D	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
defect	NULL
in	NULL
signaling	NULL
is	NULL
not	NULL
attributable	NULL
to	NULL
impairment	NULL
of	NULL
this	NULL
proximal	NULL
step	NULL
.	NULL

The	NULL
EPOR	NULL
fails	NULL
to	NULL
activate	NULL
the	NULL
MAPK	NULL
cascade	NULL
or	NULL
specific	NULL
gene	NULL
expression	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

-	NULL
To	NULL
characterize	NULL
other	NULL
signaling	NULL
pathways	NULL
known	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
the	NULL
EPOR	NULL
in	NULL
permissive	NULL
cells	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
EPO	NULL
to	NULL
induce	NULL
phosphorylation	NULL
of	NULL
MAPK	NULL
on	NULL
serine	NULL
residues	NULL
was	NULL
examined	NULL
.	NULL

Cells	NULL
were	NULL
starved	NULL
and	NULL
stimulated	NULL
with	NULL
cytokine	NULL
,	NULL
and	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
antibodies	NULL
to	NULL
phosphorylated	NULL
MAPK	NULL
.	NULL

The	NULL
immunoprecipitates	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
an	NULL
in	NULL
vitro	NULL
kinase	NULL
reaction	NULL
,	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antibodies	NULL
to	NULL
a	NULL
phosphorylated	NULL
sub-strate	NULL
,	NULL
Elk1	NULL
.	NULL

EPO	NULL
stimulation	NULL
of	NULL
a	NULL
positive	NULL
control	NULL
cell	NULL
line	NULL
HCD57	NULL
(	NULL
a	NULL
murine	NULL
,	NULL
EPO-dependent	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
)	NULL
induced	NULL
MAPK	NULL
phosphorylation	NULL
of	NULL
its	NULL
substrate	NULL
(	NULL
Fig	NULL
4	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
,	NULL
EPO	NULL
stimulation	NULL
failed	NULL
to	NULL
activate	NULL
MAPK	NULL
,	NULL
while	NULL
IL-2	NULL
stimulation	NULL
resulted	NULL
in	NULL
efficient	NULL
MAPK	NULL
induction	NULL
(	NULL
Fig	NULL
4	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Another	NULL
common	NULL
consequence	NULL
of	NULL
MAPK	NULL
activation	NULL
is	NULL
the	NULL
induction	NULL
of	NULL
specific	NULL
gene	NULL
expression	NULL
,	NULL
including	NULL
the	NULL
proto-oncogene	NULL
c-fos	NULL
.	NULL
``	NULL

To	NULL
assay	NULL
c-fos	NULL
gene	NULL
expression	NULL
,	NULL
cells	NULL
were	NULL
starved	NULL
of	NULL
cytokine	NULL
and	NULL
stimulated	NULL
with	NULL
EPO	NULL
or	NULL
IL-2	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
these	NULL
cells	NULL
,	NULL
separated	NULL
on	NULL
denaturing	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
membranes	NULL
,	NULL
and	NULL
probed	NULL
for	NULL
c-fos	NULL
or	NULL
GAPD	NULL
(	NULL
Fig	NULL
5A	NULL
)	NULL
.	NULL

Parental	NULL
HT-2	NULL
cells	NULL
lacking	NULL
the	NULL
EPOR	NULL
failed	NULL
to	NULL
induce	NULL
c-fos	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lanes	NULL
1	NULL
through	NULL
4	NULL
)	NULL
,	NULL
while	NULL
IL-2	NULL
stimulation	NULL
resulted	NULL
in	NULL
marked	NULL
c-fos	NULL
mRNA	NULL
induction	NULL
which	NULL
peaked	NULL
at	NULL
30	NULL
to	NULL
60	NULL
minutes	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lanes	NULL
5	NULL
through	NULL
HCD57	NULL
HT-2.EPOR.3	NULL
E	NULL
U	NULL
U	NULL
E	NULL
4	NULL
2	NULL
-	NULL
202	NULL
-	NULL
137	NULL
-	NULL
79	NULL
a	NULL
#	NULL
a	NULL
#	NULL
Tw	NULL
C	NULL
«	NULL
meam	NULL
-	NULL
42	NULL
-	NULL
31	NULL
unem-	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Fig	NULL
4	NULL
.	NULL

Absence	NULL
of	NULL
MAPK	NULL
induction	NULL
by	NULL
the	NULL
EPOR	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

HCDS7	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
HT-2.EPOR.3	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
through	NULL
6	NULL
)	NULL
were	NULL
starved	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
50	NULL
U/	NULL
mL	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
,	NULL
10	NULL
ng/	NULL
mL	NULL
murine	NULL
IL-4	NULL
(	NULL
4	NULL
)	NULL
,	NULL
or	NULL
10	NULL
nmol/	NULL
L	NULL
IL-2	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Total	NULL
cell	NULL
lysates	NULL
were	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-phosphoMAPK	NULL
anti-body	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
subjected	NULL
to	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
with	NULL
an	NULL
Elk1-glutathione	NULL
S-transferase	NULL
fusion	NULL
protein	NULL
,	NULL
separated	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
anti-phospho-Elk1	NULL
antibodies	NULL
.	NULL

Arrow	NULL
indicates	NULL
phosphorylated	NULL
ElK1	NULL
.	NULL

GAFFEN	NULL
ET	NULL
AL	NULL
8	NULL
%	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
EPO	NULL
stimulation	NULL
of	NULL
HT-2EPOBy	NULL
cells	NULL
also	NULL
induced	NULL
c-fos	NULL
mRNA	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lanes	NULL
14	NULL
through	NULL
17	NULL
)	NULL
,	NULL
but	NULL
EPO	NULL
stimulation	NULL
of	NULL
HT-2.EPOR.3	NULL
cells	NULL
failed	NULL
to	NULL
induce	NULL
detectable	NULL
c-fos	NULL
gene	NULL
expression	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lanes	NULL
9	NULL
through	NULL
13	NULL
)	NULL
.	NULL

As	NULL
c-fos	NULL
gene	NULL
expression	NULL
is	NULL
considered	NULL
typically	NULL
to	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
MAPK	NULL
signaling	NULL
,	NULL
this	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
lack	NULL
of	NULL
MAPK	NULL
activation	NULL
by	NULL
EPO	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
(	NULL
Fig	NULL
4	NULL
)	NULL
.	NULL

We	NULL
likewise	NULL
examined	NULL
whether	NULL
the	NULL
anti-apoptotic	NULL
gene	NULL
bei-2	NULL
is	NULL
induced	NULL
by	NULL
EPO	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
the	NULL
potent	NULL
anti-apoptotic	NULL
effect	NULL
of	NULL
EPOR	NULL
seen	NULL
in	NULL
Fig	NULL
1	NULL
,	NULL
be/-2	NULL
mRNA	NULL
was	NULL
only	NULL
weakly	NULL
induced	NULL
upon	NULL
EPO	NULL
stimulation	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
,	NULL
although	NULL
IL-2	NULL
induced	NULL
a	NULL
strong	NULL
upregulation	NULL
of	NULL
be/-2	NULL
transcripts	NULL
in	NULL
HT-2	NULL
cells	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
and	NULL
EPO	NULL
induced	NULL
be/-2	NULL
mRNA	NULL
in	NULL
HT-2.EPORBy	NULL
cells	NULL
(	NULL
Fig	NULL
5A	NULL
,	NULL
lane	NULL
17	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
suggests	NULL
that	NULL
the	NULL
anti-apoptotic	NULL
effect	NULL
of	NULL
EPOR	NULL
probably	NULL
occurs	NULL
via	NULL
a	NULL
pathway	NULL
independent	NULL
of	NULL
Bel-2	NULL
.	NULL

Recent	NULL
evidence	NULL
has	NULL
also	NULL
implicated	NULL
the	NULL
Bel-2	NULL
family	NULL
member	NULL
Bel-x1	NULL
,	NULL
in	NULL
anti-apoptotic	NULL
effects	NULL
mediated	NULL
by	NULL
the	NULL
EPOR	NULL
.	NULL

*~	NULL
``	NULL
°	NULL
However	NULL
,	NULL
we	NULL
found	NULL
by	NULL
analysis	NULL
of	NULL
RNA	NULL
that	NULL
HT-2.EPOR.3	NULL
cells	NULL
do	NULL
not	NULL
express	NULL
detectable	NULL
levels	NULL
of	NULL
bei-x	NULL
;	NULL
,	NULL
or	NULL
mRNA	NULL
,	NULL
nor	NULL
is	NULL
bei-x	NULL
;	NULL
,	NULL
mRNA	NULL
induced	NULL
by	NULL
either	NULL
IL-2	NULL
or	NULL
EPO	NULL
(	NULL
Fig	NULL
5B	NULL
)	NULL
.	NULL

Somatic	NULL
hybrids	NULL
between	NULL
HT-2	NULL
and	NULL
Ba/F3	NULL
cells	NULL
rescue	NULL
EPO	NULL
signaling	NULL
.	NULL

-	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
defect	NULL
in	NULL
EPOR	NULL
signaling	NULL
in	NULL
HT-2	NULL
cells	NULL
could	NULL
be	NULL
overcome	NULL
by	NULL
genetic	NULL
complementation	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
series	NULL
of	NULL
stable	NULL
hybridoma	NULL
cell	NULL
lines	NULL
between	NULL
HT-2.EPOR.3	NULL
and	NULL
Ba/F3	NULL
,	NULL
a	NULL
cell	NULL
line	NULL
lacking	NULL
EPOR	NULL
expression	NULL
.	NULL

Cells	NULL
were	NULL
cocultured	NULL
,	NULL
fused	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
PEG	NULL
,	NULL
and	NULL
selected	NULL
for	NULL
growth	NULL
in	NULL
50	NULL
U/mL	NULL
EPO	NULL
.	NULL

Notably	NULL
,	NULL
when	NULL
the	NULL
fusion	NULL
protocol	NULL
was	NULL
performed	NULL
with	NULL
either	NULL
HT-2.EPOR.3	NULL
or	NULL
Ba/F3	NULL
cells	NULL
alone	NULL
,	NULL
no	NULL
cell	NULL
lines	NULL
whatsoever	NULL
survived	NULL
selection	NULL
in	NULL
EPO	NULL
.	NULL

However	NULL
,	NULL
EPO-dependent	NULL
fusion	NULL
lines	NULL
were	NULL
readily	NULL
generated	NULL
when	NULL
HT-2.EPOR.3	NULL
and	NULL
Ba/F3	NULL
cells	NULL
were	NULL
mixed	NULL
in	NULL
the	NULL
fusion	NULL
reaction	NULL
.	NULL

Two	NULL
polyclonal	NULL
fusion	NULL
lines	NULL
were	NULL
chosen	NULL
for	NULL
further	NULL
analysis	NULL
,	NULL
designated	NULL
HB40	NULL
and	NULL
HB55	NULL
(	NULL
for	NULL
HT-2-Ba/F3	NULL
fused	NULL
at	NULL
40	NULL
%	NULL
or	NULL
55	NULL
%	NULL
PEG	NULL
)	NULL
.	NULL

Both	NULL
HB40	NULL
and	NULL
HB5S5	NULL
cells	NULL
proliferated	NULL
vigorously	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
,	NULL
while	NULL
Ba/F3	NULL
and	NULL
HT-2.EPOR.3	NULL
cells	NULL
showed	NULL
little	NULL
or	NULL
no	NULL
response	NULL
(	NULL
Fig	NULL
6A	NULL
)	NULL
.	NULL

The	NULL
abilities	NULL
of	NULL
HB40	NULL
and	NULL
HB55	NULL
to	NULL
proliferate	NULL
were	NULL
directly	NULL
dependent	NULL
on	NULL
the	NULL
dose	NULL
of	NULL
EPO	NULL
,	NULL
and	NULL
these	NULL
cells	NULL
responded	NULL
to	NULL
physiological	NULL
doses	NULL
of	NULL
EPO	NULL
(	NULL
Fig	NULL
6B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
'	NULL
``	NULL
I-EPO	NULL
binding	NULL
analyses	NULL
showed	NULL
that	NULL
the	NULL
fusion	NULL
cell	NULL
lines	NULL
expressed	NULL
approximately	NULL
the	NULL
same	NULL
number	NULL
of	NULL
surface	NULL
EPO	NULL
receptors	NULL
with	NULL
similar	NULL
affinities	NULL
as	NULL
the	NULL
parental	NULL
HT-2.EPOR.3	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
HT-2.EPOR.3	NULL
cells	NULL
and	NULL
the	NULL
HB40	NULL
and	NULL
HB55	NULL
cells	NULL
expressed	NULL
200	NULL
to	NULL
250	NULL
cell-surface	NULL
EPO	NULL
receptors	NULL
,	NULL
with	NULL
affinities	NULL
in	NULL
the	NULL
range	NULL
of	NULL
1,500	NULL
to	NULL
1,800	NULL
pmol/L	NULL
,	NULL
whereas	NULL
the	NULL
parental	NULL
HT-2	NULL
cells	NULL
did	NULL
not	NULL
express	NULL
detectable	NULL
receptors	NULL
for	NULL
EPO	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
restoration	NULL
of	NULL
signaling	NULL
in	NULL
the	NULL
fusion	NULL
cell	NULL
lines	NULL
is	NULL
not	NULL
simply	NULL
caused	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
receptor	NULL
number	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
STAT-5	NULL
activation	NULL
by	NULL
the	NULL
fusion	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
HT-2.EPOR.3	NULL
cells	NULL
,	NULL
HB40	NULL
and	NULL
HB55	NULL
cells	NULL
activated	NULL
STAT-5	NULL
DNA	NULL
binding	NULL
activity	NULL
vigorously	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
(	NULL
Fig	NULL
6C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
phosphorylation	NULL
of	NULL
STAT-5	NULL
proteins	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
was	NULL
also	NULL
restored	NULL
in	NULL
the	NULL
fusion	NULL
lines	NULL
(	NULL
Fig	NULL
6D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Ba/F3	NULL
cells	NULL
are	NULL
able	NULL
to	NULL
complement	NULL
the	NULL
EPOR	NULL
signaling	NULL
defect	NULL
of	NULL
HT-2	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
rescuing	NULL
the	NULL
cells	NULL
'	NULL
ability	NULL
to	NULL
grow	NULL
in	NULL
EPO	NULL
correlates	NULL
with	NULL
concurrent	NULL
restoration	NULL
of	NULL
STAT-5	NULL
activation	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
the	NULL
missing	NULL
compo-	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

ADDITIONAL	NULL
FACTOR	NULL
NEEDED	NULL
FOR	NULL
EPOR	NULL
SIGNALING	NULL
A	NULL
81	NULL
HT-2.EPORBy	NULL
HT-2+EPO	NULL
_	NULL
HT-2+IL-2	NULL
HT-2.EPOR3+EPO	NULL
_	NULL
_	NULL
+EPO	NULL
U	NULL
30°	NULL
60°	NULL
Ih	NULL
U	NULL
30'°	NULL
60°	NULL
9h	NULL
U	NULL
30°	NULL
60°	NULL
5h	NULL
9h	NULL
U	NULL
30°	NULL
60°	NULL
9h	NULL
«	NULL
»	NULL
big	NULL
s	NULL
it	NULL
®	NULL
``	NULL
:	NULL
t	NULL
¥¥H	NULL
cues	NULL
*	NULL
we	NULL
--	NULL
bel-2	NULL
1	NULL
20	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
B	NULL
5	NULL
HT-2.EPOR.3	NULL
&	NULL
EPO	NULL
IL-2	NULL
a	NULL
E	NULL
Fig	NULL
5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
EPOR	NULL
fails	NULL
to	NULL
induce	NULL
the	NULL
c-fosor	NULL
be/-2	NULL
proto-oncogene	NULL
hrs	NULL
:	NULL
U	NULL
0.5	NULL
1	NULL
4	NULL
0.5	NULL
1	NULL
4	NULL
~	NULL
mRNA	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

HT-2	NULL
,	NULL
HT-2.EPOR.3	NULL
,	NULL
and	NULL
HT-2EPOBy	NULL
cells	NULL
were	NULL
.	NULL

*	NULL
_	NULL
-	NULL
<	NULL
-BDCl-Xg	NULL
OdDOBOBDBE	NULL
-cao	NULL
1°	NULL
20	NULL
3	NULL
4	NULL
50	NULL
60	NULL
70	NULL
8	NULL
nent	NULL
(	NULL
s	NULL
)	NULL
functions	NULL
upstream	NULL
of	NULL
both	NULL
STAT-5	NULL
activation	NULL
and	NULL
proliferation	NULL
.	NULL

Finally	NULL
,	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
MAPK/c-Fos	NULL
pathway	NULL
is	NULL
likewise	NULL
rescued	NULL
in	NULL
the	NULL
fusion	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
measured	NULL
induction	NULL
of	NULL
c-fos	NULL
mRNA	NULL
.	NULL

Cells	NULL
were	NULL
starved	NULL
of	NULL
cytokines	NULL
,	NULL
stimulated	NULL
for	NULL
various	NULL
times	NULL
with	NULL
EPO	NULL
,	NULL
and	NULL
mRNA	NULL
and	NULL
Northern	NULL
blots	NULL
were	NULL
prepared	NULL
and	NULL
probed	NULL
with	NULL
P-labeled	NULL
c-fos	NULL
and	NULL
GAPD	NULL
probes	NULL
.	NULL

Induction	NULL
of	NULL
c-fos	NULL
mRNA	NULL
by	NULL
EPO	NULL
was	NULL
indeed	NULL
evident	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
6E	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
all	NULL
aspects	NULL
of	NULL
EPOR	NULL
signaling	NULL
measured	NULL
were	NULL
reconstituted	NULL
in	NULL
the	NULL
fusion	NULL
cell	NULL
lines	NULL
HB40	NULL
and	NULL
HB55	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
shows	NULL
that	NULL
the	NULL
EPOR	NULL
fails	NULL
to	NULL
mediate	NULL
STAT-5	NULL
and	NULL
MAPK	NULL
activation	NULL
or	NULL
to	NULL
deliver	NULL
proliferative	NULL
signals	NULL
in	NULL
the	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
,	NULL
HT-2	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
potentially	NULL
functional	NULL
cell-surface	NULL
EPO	NULL
receptors	NULL
that	NULL
can	NULL
mediate	NULL
JAK2	NULL
and	NULL
EPOR	NULL
phosphorylation	NULL
and	NULL
inhibit	NULL
apoptosis	NULL
.	NULL

The	NULL
signaling	NULL
defect	NULL
(	NULL
s	NULL
)	NULL
can	NULL
be	NULL
complemented	NULL
by	NULL
somatic	NULL
hybridization	NULL
between	NULL
HT-2.EPOR	NULL
cells	NULL
and	NULL
IL-3-dependent	NULL
Ba/F3	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
missing	NULL
factor	NULL
required	NULL
for	NULL
signaling	NULL
in	NULL
HT-2	NULL
cells	NULL
can	NULL
be	NULL
provided	NULL
in	NULL
trans	NULL
by	NULL
Ba/F3	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
delineate	NULL
a	NULL
dichotomy	NULL
between	NULL
the	NULL
signaling	NULL
incubated	NULL
in	NULL
media	NULL
without	NULL
grow	NULL
th	NULL
factors	NULL
for	NULL
15	NULL
hours	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
,	NULL
lanes	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
14	NULL
)	NULL
50	NULL
U/mL	NULL
EPO	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
4	NULL
,	NULL
9	NULL
through	NULL
13	NULL
,	NULL
15	NULL
through	NULL
17	NULL
)	NULL
or	NULL
10	NULL
nmol/L	NULL
IL-2	NULL
(	NULL
lanes	NULL
6	NULL
through	NULL
8	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
prepared	NULL
,	NULL
separated	NULL
on	NULL
a	NULL
denaturing	NULL
agarose/formaldehyde	NULL
gel	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
*°P-labeled	NULL
c-fos	NULL
,	NULL
bei-2	NULL
,	NULL
or	NULL
GAPD	NULL
cDNA	NULL
probes	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
EPOR	NULL
fails	NULL
to	NULL
induce	NULL
bel-x	NULL
proto-oncogene	NULL
mRNA	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

HT-2.EPOR.3	NULL
and	NULL
371.2.EPOR	NULL
cells	NULL
were	NULL
starved	NULL
as	NULL
described	NULL
in	NULL
(	NULL
A	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
4	NULL
)	NULL
,	NULL
or	NULL
IL-2	NULL
(	NULL
lanes	NULL
5	NULL
through	NULL
7	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

RNA	NULL
from	NULL
371.2.EPOR	NULL
cells	NULL
serves	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
prepared	NULL
and	NULL
blotted	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
and	NULL
probed	NULL
with	NULL
a	NULL
°°P-labeled	NULL
be/-x	NULL
cDNA	NULL
probe	NULL
derived	NULL
from	NULL
the	NULL
5°	NULL
end	NULL
of	NULL
the	NULL
gene	NULL
.	NULL

processes	NULL
that	NULL
drive	NULL
anti-apoptosis	NULL
and	NULL
those	NULL
that	NULL
induce	NULL
proliferation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
they	NULL
provide	NULL
a	NULL
valuable	NULL
platform	NULL
for	NULL
identifying	NULL
new	NULL
components	NULL
of	NULL
the	NULL
EPOR	NULL
signaling	NULL
cascade	NULL
,	NULL
which	NULL
may	NULL
also	NULL
yield	NULL
further	NULL
insights	NULL
into	NULL
signaling	NULL
mechanisms	NULL
by	NULL
other	NULL
cytokine	NULL
receptors	NULL
.	NULL

Cytokines	NULL
regulate	NULL
a	NULL
myriad	NULL
of	NULL
physiological	NULL
processes	NULL
within	NULL
their	NULL
target	NULL
cells	NULL
,	NULL
including	NULL
proliferation	NULL
,	NULL
survival	NULL
,	NULL
and	NULL
differentiation	NULL
.	NULL

Other	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
mechanisms	NULL
that	NULL
promote	NULL
cell	NULL
survival	NULL
by	NULL
inhibiting	NULL
apoptosis	NULL
are	NULL
distinct	NULL
from	NULL
those	NULL
that	NULL
trigger	NULL
cellular	NULL
proliferation	NULL
.	NULL
``	NULL

The	NULL
HT-2.EPOR.3	NULL
cell	NULL
line	NULL
described	NULL
here	NULL
supports	NULL
this	NULL
separation	NULL
of	NULL
function	NULL
,	NULL
as	NULL
the	NULL
EPOR	NULL
delivers	NULL
a	NULL
strong	NULL
anti-apoptotic	NULL
signal	NULL
while	NULL
failing	NULL
to	NULL
induce	NULL
proliferation	NULL
.	NULL

The	NULL
immature	NULL
erythroid	NULL
cell	NULL
line	NULL
J2E-NR	NULL
exhibits	NULL
similar	NULL
characteristics	NULL
with	NULL
respect	NULL
to	NULL
proliferation	NULL
;	NULL
while	NULL
the	NULL
EPOR	NULL
fails	NULL
to	NULL
induce	NULL
growth	NULL
signaling	NULL
or	NULL
differentiation	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
it	NULL
does	NULL
serve	NULL
to	NULL
enhance	NULL
cell	NULL
viability	NULL
.	NULL
``	NULL

However	NULL
,	NULL
in	NULL
many	NULL
other	NULL
cytokine-dependent	NULL
cells	NULL
,	NULL
the	NULL
EPOR	NULL
supports	NULL
proliferative	NULL
signaling	NULL
(	NULL
eg	NULL
,	NULL
32D	NULL
cells	NULL
,	NULL
Fig	NULL
2B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
may	NULL
indicate	NULL
that	NULL
certain	NULL
cell	NULL
types	NULL
need	NULL
only	NULL
an	NULL
anti-apoptotic	NULL
signal	NULL
to	NULL
transit	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
proliferate	NULL
,	NULL
while	NULL
HT-2	NULL
cells	NULL
require	NULL
an	NULL
additional	NULL
impetus	NULL
to	NULL
proliferation	NULL
that	NULL
apparently	NULL
can	NULL
be	NULL
provided	NULL
by	NULL
the	NULL
IL-2R	NULL
but	NULL
not	NULL
by	NULL
diverse	NULL
cytokine	NULL
receptors	NULL
such	NULL
as	NULL
the	NULL
EPOR	NULL
(	NULL
this	NULL
study	NULL
)	NULL
,	NULL
IL-7R	NULL
,	NULL
``	NULL
°	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

82	NULL
GAFFEN	NULL
ET	NULL
AL	NULL
C	NULL
_HT-2	NULL
EPOR.3	NULL
HB40	NULL
HB55	NULL
U	NULL
E	NULL
2	NULL
U	NULL
E	NULL
U	NULL
E	NULL
am	NULL
e	NULL
»	NULL
``	NULL
BAM	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
D	NULL
HB40	NULL
HB55	NULL
HT-2.EPOR.3	NULL
U	NULL
E	NULL
U	NULL
E	NULL
U	NULL
E	NULL
2	NULL
J	NULL
>	NULL
50000	NULL
40000	NULL
]	NULL
30000	NULL
|	NULL
20000	NULL
|	NULL
3H-Thymidine	NULL
Incorporation	NULL
(	NULL
cpm	NULL
)	NULL
UJ	NULL
200007	NULL
g	NULL
IP	NULL
:	NULL
Anti-STAT5A/B	NULL
J	NULL
&	NULL
%	NULL
W	NULL
;	NULL
Anti-P-Tyr	NULL
S	NULL
16000	NULL
|	NULL
r	NULL
Gned	NULL
l	NULL
§	NULL
8	NULL
12000	NULL
;	NULL
§	NULL
A	NULL
J	NULL
*	NULL
TC	NULL
)	NULL
sooo	NULL
|	NULL
W	NULL
:	NULL
Anti-STAT5A/B	NULL
3	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
Z	NULL
40001	NULL
T	NULL
E	NULL
-	NULL
nt-z2eror.s	NULL
_	NULL
nB4o	NULL
HBSS	NULL
®	NULL
o	NULL
.	NULL

EPO	NULL
:	NULL
0	NULL
30	NULL
60	NULL
9h	NULL
0	NULL
30	NULL
60	NULL
Sh	NULL
0	NULL
30	NULL
60	NULL
Sh	NULL
0	NULL
.001	NULL
.01	NULL
&	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
EPO	NULL
(	NULL
U/m	NULL
!	NULL
)	NULL

-c-fos	NULL
iwo	NULL
&	NULL
»	NULL
&	NULL
»	NULL
«	NULL
-	NULL
&	NULL
+	NULL
#	NULL
#	NULL
WP	NULL
-	NULL
»	NULL
a	NULL
»	NULL
a	NULL
»	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Fig	NULL
6	NULL
.	NULL

Somatic	NULL
fusions	NULL
between	NULL
HT-2.EPOR.3	NULL
and	NULL
Ba/F3	NULL
cells	NULL
restore	NULL
EPO-dependent	NULL
signaling	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Indicated	NULL
cell	NULL
lines	NULL
were	NULL
incubated	NULL
without	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
50	NULL
U/mL	NULL
EPO	NULL
or	NULL
10	NULL
%	NULL
WEHI-CM	NULL
(	NULL
as	NULL
a	NULL
source	NULL
of	NULL
IL-3	NULL
)	NULL
,	NULL
and	NULL
incorporation	NULL
measured	NULL
after	NULL
48	NULL
hours	NULL
.	NULL

(	NULL
MI	NULL
)	NULL
,	NULL
HB40	NULL
;	NULL
(	NULL
2	NULL
)	NULL
,	NULL
HBSS	NULL
;	NULL
(	NULL
B	NULL
)	NULL
,	NULL
Ba/F3	NULL
;	NULL
(	NULL
D	NULL
)	NULL
,	NULL
HT-2.EPOR.3	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Indicated	NULL
cell	NULL
lines	NULL
were	NULL
incubated	NULL
without	NULL
cytokines	NULL
or	NULL
with	NULL
various	NULL
doses	NULL
of	NULL
EPO	NULL
,	NULL
and	NULL
[	NULL
HJthymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
after	NULL
48	NULL
hours	NULL
.	NULL

(	NULL
MI	NULL
)	NULL
,	NULL
HB40	NULL
;	NULL
(	NULL
@	NULL
)	NULL
,	NULL
HBSS	NULL
.	NULL

(	NULL
C	NULL
)	NULL
HT-2.EPOR.3	NULL
,	NULL
HB40	NULL
,	NULL
and	NULL
HBSS	NULL
cells	NULL
were	NULL
rested	NULL
and	NULL
stimulated	NULL
for	NULL
15	NULL
minutes	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
50	NULL
U/mL	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
,	NULL
or	NULL
10	NULL
nmol/	NULL
L	NULL
IL-2	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
EMSA	NULL
with	NULL
the	NULL
FoyRI	NULL
probe	NULL
.	NULL

Note	NULL
that	NULL
all	NULL
lanes	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
same	NULL
gel	NULL
,	NULL
but	NULL
in	NULL
the	NULL
photograph	NULL
,	NULL
irrelevant	NULL
intervening	NULL
lanes	NULL
were	NULL
omitted	NULL
between	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
.	NULL

(	NULL
D	NULL
)	NULL
HT-2.EPOR.3	NULL
,	NULL
HB40	NULL
,	NULL
and	NULL
HBS55	NULL
cells	NULL
were	NULL
rested	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
U	NULL
)	NULL
,	NULL
EPO	NULL
(	NULL
E	NULL
)	NULL
,	NULL
or	NULL
IL-2	NULL
(	NULL
2	NULL
)	NULL
and	NULL
lysates	NULL
prepared	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-STAT-5A	NULL
and	NULL
-5B	NULL
antibodies	NULL
.	NULL

Lysates	NULL
were	NULL
separated	NULL
on	NULL
8.75	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
mem	NULL
branes	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antiphosphotyrosine	NULL
antibodies	NULL
.	NULL

Mem	NULL
branes	NULL
were	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-STAT-5A	NULL
and	NULL
-5B	NULL
antibodies	NULL
to	NULL
confirm	NULL
equivalent	NULL
loading	NULL
.	NULL

(	NULL
E	NULL
)	NULL
HT-2.EPOR.3	NULL
,	NULL
HB40	NULL
,	NULL
and	NULL
HB55	NULL
cells	NULL
were	NULL
starved	NULL
and	NULL
stimulated	NULL
with	NULL
no	NULL
cytokine	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
5	NULL
,	NULL
and	NULL
9	NULL
)	NULL
or	NULL
50	NULL
U/mL	NULL
EPO	NULL
(	NULL
lanes	NULL
2	NULL
through	NULL
4	NULL
,	NULL
6	NULL
through	NULL
8	NULL
,	NULL
and	NULL
10	NULL
through	NULL
12	NULL
)	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
5	NULL
.	NULL

RNA	NULL
was	NULL
separated	NULL
on	NULL
a	NULL
denaturing	NULL
agarose/formeldehyde	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
Zeta	NULL
Probe	NULL
membranes	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
``	NULL
P-labeled	NULL
c-fos	NULL
or	NULL
GAPD	NULL
cDNA	NULL
probes	NULL
.	NULL

IL-9R	NULL
,	NULL
*	NULL
IL-4R	NULL
,	NULL
``	NULL
``	NULL
growth	NULL
hormone	NULL
receptor	NULL
(	NULL
GHR	NULL
)	NULL
,	NULL
thrombopoi-etin	NULL
receptor	NULL
(	NULL
c-mpl	NULL
)	NULL
,	NULL
or	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
receptor	NULL
(	NULL
G-CSFR	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
HT-2	NULL
cells	NULL
provide	NULL
a	NULL
valuable	NULL
system	NULL
to	NULL
define	NULL
regions	NULL
of	NULL
the	NULL
EPOR	NULL
that	NULL
deliver	NULL
anti-apoptotic	NULL
signals	NULL
versus	NULL
those	NULL
that	NULL
mediate	NULL
proliferation	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
evidence	NULL
that	NULL
STAT-5	NULL
may	NULL
regulate	NULL
the	NULL
anti-apoptotic	NULL
signals	NULL
of	NULL
the	NULL
EPOR	NULL
in	NULL
some	NULL
cell	NULL
backgrounds	NULL
,	NULL
``	NULL
``	NULL
the	NULL
EPOR	NULL
fails	NULL
to	NULL
activate	NULL
any	NULL
known	NULL
STAT	NULL
factors	NULL
in	NULL
HT-2	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

ADDITIONAL	NULL
FACTOR	NULL
NEEDED	NULL
FOR	NULL
EPOR	NULL
SIGNALING	NULL
Table	NULL
1	NULL
.	NULL

Determination	NULL
of	NULL
Cell-Surface	NULL
Expression	NULL
of	NULL
EPO	NULL
Receptors	NULL
by	NULL
Scatchard	NULL
Analysis	NULL
Cell	NULL
Line	NULL
Receptor	NULL
No	NULL
.	NULL

kd	NULL
(	NULL
pmol/L	NULL
)	NULL
32D.EPOR	NULL
1,300	NULL
300	NULL
HT-2	NULL
ND	NULL
ND	NULL
HT-2EPOR.3	NULL
250	NULL
1,800	NULL
HB40	NULL
200	NULL
1,600	NULL
HBS55	NULL
200	NULL
1,500	NULL
Abbreviation	NULL
:	NULL
ND	NULL
,	NULL
not	NULL
detectable	NULL
.	NULL

cells	NULL
,	NULL
thus	NULL
arguing	NULL
that	NULL
STAT-5	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
this	NULL
particular	NULL
anti-apoptotic	NULL
pathway	NULL
.	NULL

Likewise	NULL
,	NULL
despite	NULL
evidence	NULL
that	NULL
induction	NULL
of	NULL
the	NULL
API	NULL
transcription	NULL
factor	NULL
(	NULL
which	NULL
includes	NULL
the	NULL
c-Fos	NULL
proto-oncogene	NULL
)	NULL
by	NULL
the	NULL
MAPK	NULL
pathway	NULL
has	NULL
been	NULL
linked	NULL
to	NULL
protection	NULL
from	NULL
apoptosis	NULL
,	NULL
``	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
MAPK	NULL
activation	NULL
is	NULL
not	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
apoptosis	NULL
in	NULL
the	NULL
HT-2	NULL
cell	NULL
background	NULL
,	NULL
because	NULL
this	NULL
pathway	NULL
is	NULL
not	NULL
engaged	NULL
by	NULL
the	NULL
EPOR	NULL
.	NULL

In	NULL
32D	NULL
cells	NULL
,	NULL
the	NULL
EPOR	NULL
is	NULL
known	NULL
to	NULL
induce	NULL
Bcl-2	NULL
and	NULL
Bel-x	NULL
;	NULL
,	NULL
to	NULL
effect	NULL
apoptosis	NULL
inhibition.©	NULL
``	NULL
However	NULL
,	NULL
neither	NULL
of	NULL
these	NULL
genes	NULL
is	NULL
significantly	NULL
induced	NULL
by	NULL
the	NULL
EPOR	NULL
in	NULL
HT-2	NULL
cells	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
molecular	NULL
mechanism	NULL
underlying	NULL
EPOR-mediated	NULL
apoptotic	NULL
inhibition	NULL
in	NULL
this	NULL
context	NULL
is	NULL
distinct	NULL
from	NULL
recognized	NULL
pathways	NULL
and	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
some	NULL
developmental	NULL
events	NULL
appear	NULL
to	NULL
require	NULL
cytokines	NULL
mainly	NULL
to	NULL
prevent	NULL
apoptosis	NULL
,	NULL
while	NULL
others	NULL
appear	NULL
to	NULL
need	NULL
additional	NULL
proliferative	NULL
signals	NULL
.	NULL
``	NULL

''	NULL
Although	NULL
the	NULL
EPOR	NULL
does	NULL
exert	NULL
anti-apoptotic	NULL
effects	NULL
***	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
,	NULL
prevention	NULL
of	NULL
apoptosis	NULL
in	NULL
erythroid	NULL
progenitors	NULL
is	NULL
probably	NULL
not	NULL
sufficient	NULL
to	NULL
eliminate	NULL
their	NULL
dependence	NULL
on	NULL
EPO	NULL
for	NULL
maturation	NULL
.	NULL
``	NULL

Specifically	NULL
,	NULL
in	NULL
mice	NULL
expressing	NULL
a	NULL
be/-2	NULL
transgene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
an	NULL
erythroid	NULL
promoter	NULL
,	NULL
growth	NULL
of	NULL
erythroid	NULL
progenitors	NULL
in	NULL
vitro	NULL
is	NULL
impaired	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

While	NULL
apoptosis	NULL
of	NULL
colony	NULL
forming	NULL
units-erythroid	NULL
(	NULL
CFU-E	NULL
)	NULL
is	NULL
delayed	NULL
in	NULL
these	NULL
transgenic	NULL
mice	NULL
,	NULL
no	NULL
spontaneously	NULL
differentiating	NULL
colonies	NULL
are	NULL
found	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EPO	NULL
.	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
see	NULL
the	NULL
results	NULL
of	NULL
crossing	NULL
these	NULL
mice	NULL
with	NULL
EPO-~-	NULL
or	NULL
EPOR~~-	NULL
mice	NULL
``	NULL
to	NULL
determine	NULL
whether	NULL
differentiation	NULL
in	NULL
vivo	NULL
is	NULL
equally	NULL
affected	NULL
.	NULL

However	NULL
,	NULL
using	NULL
a	NULL
beil-2	NULL
transgene	NULL
to	NULL
inhibit	NULL
apoptosis	NULL
in	NULL
erythroid	NULL
progenitors	NULL
may	NULL
not	NULL
mimic	NULL
native	NULL
anti-apoptotic	NULL
signaling	NULL
by	NULL
the	NULL
EPOR	NULL
,	NULL
because	NULL
our	NULL
work	NULL
shows	NULL
that	NULL
the	NULL
EPOR	NULL
is	NULL
able	NULL
to	NULL
prevent	NULL
apoptosis	NULL
without	NULL
inducing	NULL
be/-2	NULL
mRNA	NULL
significantly	NULL
(	NULL
Figs	NULL
1	NULL
and	NULL
5A	NULL
)	NULL
,	NULL
and	NULL
because	NULL
Bcl-2	NULL
is	NULL
apparently	NULL
not	NULL
expressed	NULL
in	NULL
erythroid	NULL
progenitors	NULL
.	NULL
``	NULL

Another	NULL
in	NULL
vivo	NULL
system	NULL
illustrating	NULL
the	NULL
importance	NULL
of	NULL
apoptotic	NULL
inhibition	NULL
is	NULL
mice	NULL
lacking	NULL
the	NULL
IL-7Ra	NULL
chain	NULL
(	NULL
or	NULL
its	NULL
partner	NULL
,	NULL
yc	NULL
)	NULL
.4	NULL
%	NULL
IL-7Ra~'~	NULL
mice	NULL
are	NULL
characterized	NULL
by	NULL
profound	NULL
immu-nodeficiency	NULL
,	NULL
lacking	NULL
mature	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

When	NULL
these	NULL
mice	NULL
were	NULL
crossed	NULL
with	NULL
animals	NULL
that	NULL
overexpress	NULL
the	NULL
human	NULL
be/-2	NULL
gene	NULL
,	NULL
T-cell	NULL
development	NULL
was	NULL
rescued	NULL
,	NULL
but	NULL
not	NULL
B-cell	NULL
develop-ment	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
the	NULL
IL-7-derived	NULL
signal	NULL
necessary	NULL
for	NULL
T-cell	NULL
maturation	NULL
can	NULL
be	NULL
replaced	NULL
solely	NULL
by	NULL
inhibiting	NULL
apoptosis	NULL
,	NULL
but	NULL
B-cell	NULL
differentiation	NULL
requires	NULL
additional	NULL
signals	NULL
from	NULL
the	NULL
IL-7R	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
EPO-EPOR	NULL
system	NULL
appears	NULL
to	NULL
require	NULL
such	NULL
additional	NULL
signals	NULL
for	NULL
erythroid	NULL
development	NULL
.	NULL

The	NULL
dominant	NULL
paradigm	NULL
of	NULL
the	NULL
JAK-STAT	NULL
pathway	NULL
indicates	NULL
that	NULL
STAT	NULL
factors	NULL
are	NULL
recruited	NULL
to	NULL
the	NULL
receptor	NULL
complex	NULL
following	NULL
phosphorylation	NULL
of	NULL
receptor	NULL
tyrosine	NULL
residues	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
EPOR	NULL
,	NULL
this	NULL
model	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
severe	NULL
diminution	NULL
in	NULL
STAT-5	NULL
activation	NULL
by	NULL
EPO	NULL
receptor	NULL
mutants	NULL
that	NULL
lack	NULL
cytoplas-	NULL
83	NULL
mic	NULL
tyrosine	NULL
residues	NULL
.	NULL

``	NULL
``	NULL
``	NULL
*	NULL
``	NULL
``	NULL
However	NULL
,	NULL
the	NULL
block	NULL
in	NULL
JAK-STAT	NULL
signaling	NULL
in	NULL
this	NULL
study	NULL
shows	NULL
that	NULL
there	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
an	NULL
additional	NULL
component	NULL
of	NULL
this	NULL
pathway	NULL
that	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
recognized	NULL
.	NULL

Although	NULL
very	NULL
proximal	NULL
signals	NULL
are	NULL
intact	NULL
in	NULL
this	NULL
pathway	NULL
(	NULL
eg	NULL
,	NULL
phosphorylation	NULL
of	NULL
JAK2	NULL
and	NULL
the	NULL
EPOR	NULL
,	NULL
Figs	NULL
3A	NULL
and	NULL
3D	NULL
)	NULL
,	NULL
phosphorylation	NULL
of	NULL
STAT-5	NULL
is	NULL
impaired	NULL
(	NULL
Fig	NULL
3C	NULL
)	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
potential	NULL
phosphotyro-sine	NULL
docking	NULL
sites	NULL
on	NULL
the	NULL
EPOR	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
complexes	NULL
induced	NULL
by	NULL
EPO	NULL
in	NULL
371.2	NULL
cells	NULL
migrate	NULL
slightly	NULL
faster	NULL
than	NULL
does	NULL
the	NULL
IL-2-induced	NULL
STAT-5	NULL
complex	NULL
in	NULL
HT-2	NULL
cells	NULL
or	NULL
the	NULL
EPO-induced	NULL
STAT-5	NULL
complex	NULL
in	NULL
HB40	NULL
and	NULL
HB55	NULL
cells	NULL
We	NULL
have	NULL
not	NULL
yet	NULL
determined	NULL
the	NULL
biochemical	NULL
basis	NULL
for	NULL
this	NULL
difference	NULL
.	NULL

There	NULL
are	NULL
two	NULL
opposing	NULL
hypotheses	NULL
to	NULL
explain	NULL
the	NULL
lack	NULL
of	NULL
EPOR	NULL
signaling	NULL
in	NULL
the	NULL
HT-2	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
most	NULL
likely	NULL
explanation	NULL
is	NULL
that	NULL
the	NULL
cells	NULL
are	NULL
missing	NULL
a	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
necessary	NULL
to	NULL
mediate	NULL
signaling	NULL
.	NULL

Supporting	NULL
evidence	NULL
comes	NULL
from	NULL
the	NULL
somatic	NULL
fusions	NULL
with	NULL
Ba/F3	NULL
cells	NULL
,	NULL
which	NULL
can	NULL
complement	NULL
the	NULL
lack	NULL
of	NULL
function	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
.	NULL

The	NULL
resulting	NULL
fusion	NULL
cell	NULL
lines	NULL
rescue	NULL
not	NULL
only	NULL
proliferation	NULL
signaling	NULL
,	NULL
but	NULL
also	NULL
STAT-5	NULL
activation	NULL
and	NULL
proto-oncogene	NULL
induction	NULL
.	NULL

Although	NULL
the	NULL
nature	NULL
of	NULL
this	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
can	NULL
only	NULL
be	NULL
determined	NULL
by	NULL
isolating	NULL
a	NULL
gene	NULL
from	NULL
an	NULL
EPO-responsive	NULL
cell	NULL
line	NULL
that	NULL
can	NULL
rescue	NULL
the	NULL
proliferative	NULL
defect	NULL
,	NULL
some	NULL
possibilities	NULL
include	NULL
an	NULL
additional	NULL
EPOR	NULL
subunit	NULL
or	NULL
an	NULL
adapter	NULL
molecule	NULL
that	NULL
might	NULL
couple	NULL
STAT-5	NULL
to	NULL
JAK2	NULL
or	NULL
to	NULL
the	NULL
EPOR	NULL
.	NULL

Indeed	NULL
,	NULL
there	NULL
have	NULL
been	NULL
hints	NULL
that	NULL
the	NULL
EPOR	NULL
complex	NULL
might	NULL
contain	NULL
an	NULL
additional	NULL
subunit	NULL
``	NULL
;	NULL
in	NULL
this	NULL
scenario	NULL
,	NULL
the	NULL
missing	NULL
receptor	NULL
would	NULL
be	NULL
expressed	NULL
in	NULL
most	NULL
cell	NULL
lines	NULL
but	NULL
would	NULL
be	NULL
absent	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

We	NULL
are	NULL
confident	NULL
that	NULL
the	NULL
missing	NULL
factor	NULL
is	NULL
not	NULL
the	NULL
adapter	NULL
Shc	NULL
,	NULL
because	NULL
IL-2	NULL
signaling	NULL
through	NULL
Shc	NULL
that	NULL
leads	NULL
to	NULL
MAPK	NULL
and	NULL
c-fos	NULL
mRNA	NULL
induction	NULL
proceeds	NULL
normally	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
(	NULL
Figs	NULL
4	NULL
and	NULL
5	NULL
,	NULL
and	NULL
refs	NULL
34	NULL
,	NULL
74	NULL
,	NULL
and	NULL
75	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
it	NULL
is	NULL
formally	NULL
possible	NULL
that	NULL
HT-2	NULL
cells	NULL
express	NULL
an	NULL
overabundance	NULL
of	NULL
a	NULL
suppressor	NULL
factor	NULL
that	NULL
inhibits	NULL
the	NULL
EPOR	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
known	NULL
that	NULL
the	NULL
tyrosine	NULL
phosphatases	NULL
SHP-1	NULL
and	NULL
SHP-2	NULL
are	NULL
involved	NULL
in	NULL
EPOR	NULL
signaling	NULL
,	NULL
``	NULL
*	NULL
``	NULL
``	NULL
mRNA	NULL
levels	NULL
of	NULL
SHP-1	NULL
and	NULL
SHP-2	NULL
in	NULL
HT-2	NULL
cells	NULL
are	NULL
comparable	NULL
to	NULL
those	NULL
in	NULL
EPO-responsive	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HCD357	NULL
and	NULL
Ba/F3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
cytokine	NULL
inhibitors	NULL
of	NULL
the	NULL
SOCS/CIS	NULL
family	NULL
``	NULL
``	NULL
are	NULL
responsible	NULL
,	NULL
because	NULL
:	NULL
(	NULL
1	NULL
)	NULL
the	NULL
STAT	NULL
downregulation	NULL
that	NULL
occurs	NULL
upon	NULL
SOCS	NULL
activation	NULL
is	NULL
linked	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
JAK	NULL
activity	NULL
,	NULL
while	NULL
JAK2	NULL
activation	NULL
by	NULL
the	NULL
EPOR	NULL
is	NULL
retained	NULL
in	NULL
HT-2	NULL
cells	NULL
(	NULL
Fig	NULL
3	NULL
)	NULL
;	NULL
(	NULL
2	NULL
)	NULL
none	NULL
of	NULL
the	NULL
SOCS	NULL
family	NULL
members	NULL
identified	NULL
so	NULL
far	NULL
are	NULL
specific	NULL
to	NULL
the	NULL
and	NULL
IL-2	NULL
,	NULL
IL-7	NULL
,	NULL
and	NULL
IL-9	NULL
can	NULL
activate	NULL
STAT-5	NULL
vigorously	NULL
in	NULL
HT-2	NULL
cells	NULL
``	NULL
``	NULL
;	NULL
and	NULL
(	NULL
3	NULL
)	NULL
the	NULL
EPOR	NULL
can	NULL
pair	NULL
with	NULL
EPORB	NULL
to	NULL
activate	NULL
JAK2	NULL
and	NULL
STAT-5*	NULL
and	NULL
is	NULL
thus	NULL
unlikely	NULL
to	NULL
carry	NULL
any	NULL
other	NULL
dominant	NULL
suppressor	NULL
molecule	NULL
(	NULL
s	NULL
)	NULL
that	NULL
inhibits	NULL
proximal	NULL
signaling	NULL
within	NULL
this	NULL
hybrid	NULL
receptor	NULL
complex	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
available	NULL
evidence	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
HT-2	NULL
cells	NULL
are	NULL
missing	NULL
a	NULL
necessary	NULL
signaling	NULL
component	NULL
that	NULL
links	NULL
the	NULL
EPOR	NULL
to	NULL
STAT-5	NULL
,	NULL
MAPK	NULL
,	NULL
and	NULL
proliferation	NULL
signaling	NULL
.	NULL

An	NULL
issue	NULL
of	NULL
considerable	NULL
interest	NULL
is	NULL
whether	NULL
cytokine	NULL
signaling	NULL
differs	NULL
depending	NULL
on	NULL
cell	NULL
context	NULL
.	NULL

Although	NULL
there	NULL
are	NULL
dozens	NULL
of	NULL
cytokines	NULL
,	NULL
each	NULL
with	NULL
a	NULL
specific	NULL
receptor	NULL
,	NULL
the	NULL
downstream	NULL
events	NULL
that	NULL
follow	NULL
receptor	NULL
ligation	NULL
are	NULL
remarkably	NULL
similar	NULL
among	NULL
members	NULL
of	NULL
the	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
;	NULL
eg	NULL
,	NULL
both	NULL
the	NULL
IL-2R	NULL
and	NULL
EPOR	NULL
activate	NULL
STAT-5	NULL
,	NULL
c-Fos	NULL
,	NULL
Bel-2	NULL
,	NULL
MAPK	NULL
,	NULL
IRS-2	NULL
,	NULL
and	NULL
PI3K	NULL
.	NULL

*	NULL
``	NULL
Do	NULL
the	NULL
target	NULL
cells	NULL
of	NULL
different	NULL
cytokines	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

84	NULL
``	NULL
interpret	NULL
``	NULL
these	NULL
signals	NULL
differently	NULL
,	NULL
or	NULL
is	NULL
the	NULL
basis	NULL
for	NULL
this	NULL
dichotomy	NULL
simply	NULL
their	NULL
anatomical	NULL
location	NULL
?	NULL

To	NULL
address	NULL
this	NULL
question	NULL
in	NULL
the	NULL
context	NULL
of	NULL
homodimeric	NULL
receptors	NULL
such	NULL
as	NULL
the	NULL
EPOR	NULL
,	NULL
recent	NULL
work	NULL
using	NULL
an	NULL
in	NULL
vivo	NULL
differentiation	NULL
system	NULL
showed	NULL
that	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
EPOR	NULL
can	NULL
be	NULL
substituted	NULL
with	NULL
the	NULL
cytoplasmic	NULL
domains	NULL
of	NULL
diverse	NULL
cytokine	NULL
receptors	NULL
(	NULL
G-CSFR	NULL
,	NULL
c-mpl	NULL
,	NULL
and	NULL
GHR	NULL
)	NULL
yet	NULL
exhibit	NULL
similar	NULL
signaling	NULL
outcomes	NULL
with	NULL
regard	NULL
to	NULL
erythropoiesis	NULL
,	NULL
thus	NULL
favoring	NULL
the	NULL
notion	NULL
that	NULL
cytokine	NULL
signals	NULL
are	NULL
generally	NULL
replaceable	NULL
.	NULL
``	NULL

Similarly	NULL
,	NULL
prolactin	NULL
and	NULL
its	NULL
receptor	NULL
can	NULL
substitute	NULL
for	NULL
the	NULL
EPOR	NULL
in	NULL
driving	NULL
differentiation	NULL
of	NULL
erythrocytes	NULL
in	NULL
vitro	NULL
.	NULL
``	NULL

In	NULL
an	NULL
analogous	NULL
study	NULL
,	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
IL-2Rf	NULL
chain	NULL
was	NULL
found	NULL
to	NULL
substitute	NULL
functionally	NULL
for	NULL
the	NULL
IL-7Ra	NULL
chain	NULL
in	NULL
driving	NULL
proliferation	NULL
of	NULL
B	NULL
cells	NULL
in	NULL
an	NULL
ex	NULL
vivo	NULL
culture	NULL
system	NULL
.	NULL

*	NULL
However	NULL
,	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
suggest	NULL
that	NULL
the	NULL
EPOR	NULL
can	NULL
not	NULL
replace	NULL
the	NULL
IL-2R	NULL
,	NULL
despite	NULL
the	NULL
apparent	NULL
similarity	NULL
in	NULL
the	NULL
intracellular	NULL
signaling	NULL
molecules	NULL
engaged	NULL
by	NULL
these	NULL
receptors	NULL
.	NULL

Although	NULL
the	NULL
restoration	NULL
of	NULL
STAT-5	NULL
activation	NULL
in	NULL
the	NULL
HT-2-Ba/F3	NULL
hybridomas	NULL
implies	NULL
a	NULL
link	NULL
between	NULL
STAT-5	NULL
function	NULL
and	NULL
proliferation	NULL
,	NULL
STAT-5	NULL
activation	NULL
is	NULL
clearly	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
proliferation	NULL
in	NULL
the	NULL
HT-2	NULL
cell	NULL
background	NULL
.	NULL

First	NULL
,	NULL
it	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
that	NULL
IL-7R	NULL
signaling	NULL
fails	NULL
to	NULL
support	NULL
proliferation	NULL
in	NULL
HT-2	NULL
cells	NULL
,	NULL
despite	NULL
a	NULL
vigorous	NULL
induction	NULL
of	NULL
STAT-5	NULL
DNA	NULL
binding	NULL
.	NULL
``	NULL

Second	NULL
,	NULL
the	NULL
IL-9R	NULL
activates	NULL
STAT-5	NULL
(	NULL
and	NULL
STAT-1	NULL
and	NULL
STAT-3	NULL
)	NULL
quite	NULL
well	NULL
in	NULL
HT-2	NULL
cells	NULL
and	NULL
also	NULL
mediates	NULL
an	NULL
anti-apoptotic	NULL
response	NULL
,	NULL
but	NULL
does	NULL
not	NULL
permit	NULL
proliferation	NULL
.	NULL
``	NULL

Finally	NULL
,	NULL
the	NULL
IL-4R	NULL
also	NULL
induces	NULL
JAK-STAT	NULL
activation	NULL
(	NULL
in	NULL
this	NULL
case	NULL
,	NULL
STAT-6	NULL
)	NULL
without	NULL
driving	NULL
proliferation	NULL
of	NULL
HT-2	NULL
cells	NULL
.	NULL
``	NULL

At	NULL
present	NULL
,	NULL
it	NULL
is	NULL
unclear	NULL
precisely	NULL
how	NULL
IL-2	NULL
signaling	NULL
differs	NULL
from	NULL
that	NULL
of	NULL
the	NULL
other	NULL
yc-utilizing	NULL
cytokine	NULL
receptors	NULL
and	NULL
the	NULL
EPOR	NULL
to	NULL
induce	NULL
proliferation	NULL
in	NULL
HT-2	NULL
cells	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
EPOR	NULL
to	NULL
signal	NULL
in	NULL
a	NULL
T-cell	NULL
background	NULL
has	NULL
also	NULL
been	NULL
described	NULL
for	NULL
sublines	NULL
of	NULL
the	NULL
IL-2-dependent	NULL
T-cell	NULL
line	NULL
CTLL	NULL
transfected	NULL
with	NULL
the	NULL
EPOR	NULL
.	NULL
``	NULL

''	NULL
In	NULL
this	NULL
case	NULL
,	NULL
the	NULL
cells	NULL
'	NULL
nonresponsiveness	NULL
was	NULL
attributed	NULL
to	NULL
the	NULL
failure	NULL
of	NULL
JAK2	NULL
to	NULL
associate	NULL
with	NULL
the	NULL
EPOR	NULL
.	NULL

This	NULL
mechanism	NULL
contrasts	NULL
with	NULL
our	NULL
results	NULL
in	NULL
HT-2.EPOR.3	NULL
cells	NULL
in	NULL
which	NULL
JAK2	NULL
is	NULL
potently	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
EPO	NULL
,	NULL
while	NULL
STAT-5	NULL
activation	NULL
is	NULL
impaired	NULL
.	NULL

Because	NULL
IL-2	NULL
functions	NULL
as	NULL
a	NULL
growth	NULL
factor	NULL
for	NULL
mature	NULL
,	NULL
peripheral	NULL
T	NULL
cells	NULL
such	NULL
as	NULL
HT-2	NULL
and	NULL
CTLL	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
permissivity	NULL
to	NULL
signaling	NULL
in	NULL
the	NULL
HT-2	NULL
and	NULL
CTLL	NULL
lines	NULL
reflects	NULL
their	NULL
biologic	NULL
origins	NULL
.	NULL

It	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
whether	NULL
EPOR-mediated	NULL
signal	NULL
transduction	NULL
can	NULL
occur	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
present	NULL
report	NULL
describes	NULL
a	NULL
unique	NULL
cell	NULL
context	NULL
in	NULL
which	NULL
signaling	NULL
by	NULL
the	NULL
EPOR	NULL
is	NULL
impaired	NULL
,	NULL
despite	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
highly	NULL
related	NULL
cytokine	NULL
(	NULL
IL-2	NULL
)	NULL
to	NULL
trigger	NULL
the	NULL
same	NULL
signaling	NULL
pathways	NULL
.	NULL

This	NULL
system	NULL
will	NULL
serve	NULL
as	NULL
a	NULL
valuable	NULL
tool	NULL
for	NULL
identifying	NULL
essential	NULL
components	NULL
that	NULL
link	NULL
the	NULL
EPOR	NULL
to	NULL
the	NULL
JAK-STAT	NULL
,	NULL
MAPK	NULL
pathways	NULL
,	NULL
and	NULL
proliferative	NULL
machinery	NULL
.	NULL

ACKNOWLEDGMENT	NULL
The	NULL
authors	NULL
acknowledge	NULL
the	NULL
valuable	NULL
assistance	NULL
of	NULL
John	NULL
Carroll	NULL
,	NULL
Neile	NULL
Shea	NULL
,	NULL
and	NULL
Heather	NULL
Livesay	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
,	NULL
and	NULL
Dr	NULL
N.	NULL
Abraham	NULL
for	NULL
critical	NULL
reading	NULL
.	NULL

Annexin-GFP	NULL
was	NULL
the	NULL
kind	NULL
gift	NULL
of	NULL
Dr	NULL
Joel	NULL
Ernst	NULL
,	NULL
and	NULL
371.2	NULL
cells	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
Morris	NULL
White	NULL
(	NULL
Joslin	NULL
Diabetes	NULL
Center	NULL
,	NULL
Harvard	NULL
University	NULL
)	NULL
.	NULL

IL-2	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Chiron	NULL
Corporation	NULL
,	NULL
and	NULL
EPO	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Ortho	NULL
Biotech	NULL
.	NULL

GAFFEN	NULL
ET	NULL
AL	NULL
REFERENCES	NULL
1	NULL
.	NULL

D'Andrea	NULL
AD	NULL
,	NULL
Lodish	NULL
HF	NULL
,	NULL
Wong	NULL
GG	NULL
:	NULL
Expression	NULL
cloning	NULL
of	NULL
the	NULL
murine	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Cell	NULL
57:277	NULL
,	NULL
1989	NULL
2	NULL
.	NULL

Lin	NULL
C-S	NULL
,	NULL
Lim	NULL
S-K	NULL
,	NULL
D	NULL
'	NULL
Agati	NULL
V	NULL
,	NULL
Costantini	NULL
F	NULL
:	NULL
Differential	NULL
effects	NULL
of	NULL
an	NULL
erythropoietin	NULL
receptor	NULL
gene	NULL
disruption	NULL
on	NULL
primitive	NULL
and	NULL
definitive	NULL
erythropoiesis	NULL
.	NULL

Gen	NULL
Dev	NULL
10:154	NULL
,	NULL
1996	NULL
3	NULL
.	NULL

Wu	NULL
H	NULL
,	NULL
Liu	NULL
X	NULL
,	NULL
Jaenisch	NULL
R	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Generation	NULL
of	NULL
committed	NULL
erythroid	NULL
BFU-E	NULL
and	NULL
CFU-E	NULL
progenitors	NULL
does	NULL
not	NULL
require	NULL
erythropoietin	NULL
or	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Cell	NULL
83:59	NULL
,	NULL
1995	NULL
4	NULL
.	NULL

Damen	NULL
J	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Early	NULL
events	NULL
in	NULL
erythropoietin-induced	NULL
signaling	NULL
.	NULL

Exp	NULL
Hematol	NULL
24:1455	NULL
,	NULL
1996	NULL
5	NULL
.	NULL

Bazan	NULL
JF	NULL
:	NULL
Structural	NULL
design	NULL
and	NULL
molecular	NULL
evolution	NULL
of	NULL
a	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
87:6934	NULL
,	NULL
1990	NULL
6	NULL
.	NULL

Longmore	NULL
GD	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
An	NULL
activating	NULL
mutation	NULL
in	NULL
the	NULL
murine	NULL
erythropoietin	NULL
receptor	NULL
induces	NULL
erythroleukemia	NULL
in	NULL
mice	NULL
:	NULL
A	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
oncogene	NULL
.	NULL

Cell	NULL
67:1089	NULL
,	NULL
1991	NULL
7	NULL
.	NULL

Watowich	NULL
SS	NULL
,	NULL
Yoshimura	NULL
A	NULL
,	NULL
Longmore	NULL
GD	NULL
,	NULL
Hilton	NULL
DJ	NULL
,	NULL
Yoshimura	NULL
Y	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Homodimerization	NULL
and	NULL
constitutive	NULL
activation	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:2140	NULL
,	NULL
1992	NULL
8	NULL
.	NULL

Yoshimura	NULL
A	NULL
,	NULL
Longmore	NULL
G	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Point	NULL
mutation	NULL
in	NULL
the	NULL
exoplasmic	NULL
domain	NULL
of	NULL
the	NULL
erythropietin	NULL
receptor	NULL
resulting	NULL
in	NULL
hormone-independent	NULL
activation	NULL
and	NULL
tumorigenicity	NULL
.	NULL

Nature	NULL
348:647	NULL
,	NULL
1990	NULL
9	NULL
.	NULL

Watowich	NULL
SS	NULL
,	NULL
Hilton	NULL
DJ	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Activation	NULL
and	NULL
inhibition	NULL
of	NULL
erythropoietin	NULL
receptor	NULL
function	NULL
:	NULL
Role	NULL
of	NULL
receptor	NULL
dimerization	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
14:3535	NULL
,	NULL
1994	NULL
10	NULL
.	NULL

Livnah	NULL
O	NULL
,	NULL
Stura	NULL
EA	NULL
,	NULL
Johnson	NULL
DL	NULL
,	NULL
Middleton	NULL
SA	NULL
,	NULL
Mulcahy	NULL
LS	NULL
,	NULL
Wrighton	NULL
NC	NULL
,	NULL
Dower	NULL
WJ	NULL
,	NULL
Jolliffe	NULL
LK	NULL
,	NULL
Wilson	NULL
IA	NULL
:	NULL
Functional	NULL
mimicry	NULL
of	NULL
a	NULL
protein	NULL
hormone	NULL
by	NULL
a	NULL
peptide	NULL
agonist	NULL
:	NULL
The	NULL
EPO	NULL
receptor	NULL
complex	NULL
at	NULL
2.8A	NULL
.	NULL

Science	NULL
273:464	NULL
,	NULL
1996	NULL
11	NULL
.	NULL

Miura	NULL
O	NULL
,	NULL
D'Andrea	NULL
AD	NULL
,	NULL
Kabat	NULL
D	NULL
,	NULL
Thie	NULL
JN	NULL
:	NULL
Induction	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
by	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
correlates	NULL
with	NULL
mitogen-esis	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
11:4895	NULL
,	NULL
1991	NULL
12	NULL
.	NULL

Dusanter-Fort	NULL
I	NULL
,	NULL
Casadevall	NULL
N	NULL
,	NULL
Lacombe	NULL
C	NULL
,	NULL
Muller	NULL
O	NULL
,	NULL
Billat	NULL
C	NULL
,	NULL
Fischer	NULL
S	NULL
,	NULL
Mayeux	NULL
P	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
its	NULL
own	NULL
receptor	NULL
in	NULL
human	NULL
erthropoietin-responsive	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
267:10670	NULL
,	NULL
1992	NULL
13	NULL
.	NULL

Yoshimura	NULL
A	NULL
,	NULL
Lodish	NULL
H	NULL
:	NULL
;	NULL
In	NULL
vitro	NULL
phosphorylation	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
and	NULL
an	NULL
associated	NULL
protein	NULL
pp130	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
12:706	NULL
,	NULL
1992	NULL
14	NULL
.	NULL

Witthuhn	NULL
BA	NULL
,	NULL
Quelle	NULL
FW	NULL
,	NULL
Silvennoinen	NULL
O	NULL
,	NULL
Yi	NULL
T	NULL
,	NULL
Tang	NULL
B	NULL
,	NULL
Miura	NULL
O	NULL
,	NULL
Ihle	NULL
JN	NULL
:	NULL
JAK2	NULL
associates	NULL
with	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
and	NULL
is	NULL
tyrosine	NULL
phosphorylated	NULL
and	NULL
activated	NULL
following	NULL
stimulation	NULL
with	NULL
erythropoietin	NULL
.	NULL

Cell	NULL
74:227	NULL
,	NULL
1993	NULL
15	NULL
.	NULL

Gouilleux	NULL
F	NULL
,	NULL
Pallard	NULL
C	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
Haldosen	NULL
L-A	NULL
,	NULL
Norstedt	NULL
G	NULL
,	NULL
Levy	NULL
D	NULL
,	NULL
Groner	NULL
B	NULL
:	NULL
Prolactin	NULL
,	NULL
growth	NULL
hormone	NULL
,	NULL
erythropoietin	NULL
and	NULL
granulocyote-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
induce	NULL
MGF-Stat5	NULL
DNA	NULL
bindng	NULL
activity	NULL
.	NULL

EMBO	NULL
J	NULL
14:2005	NULL
,	NULL
1995	NULL
16	NULL
.	NULL

Liu	NULL
KD	NULL
,	NULL
Gaffen	NULL
SL	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
JAK-STAT	NULL
signaling	NULL
by	NULL
cytokine	NULL
receptors	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
10:271	NULL
,	NULL
1998	NULL
17	NULL
.	NULL

Yoshimura	NULL
A	NULL
,	NULL
Ichihara	NULL
M	NULL
,	NULL
Kinjyo	NULL
I	NULL
,	NULL
Moriyama	NULL
M	NULL
,	NULL
Copeland	NULL
NG	NULL
,	NULL
Gilbert	NULL
DJ	NULL
,	NULL
Jenkins	NULL
NA	NULL
,	NULL
Hara	NULL
T	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
Mouse	NULL
oncostatin	NULL
M	NULL
:	NULL
An	NULL
immediate	NULL
early	NULL
gene	NULL
induced	NULL
by	NULL
multiple	NULL
cytokines	NULL
through	NULL
the	NULL
JAK-STATS5	NULL
pathway	NULL
.	NULL

EMBO	NULL
J	NULL
15:1055	NULL
,	NULL
1996	NULL
18	NULL
.	NULL

Matsumoto	NULL
A	NULL
,	NULL
Masuhara	NULL
M	NULL
,	NULL
Mitsui	NULL
K	NULL
,	NULL
Yokouchi	NULL
M	NULL
,	NULL
Ohtsubo	NULL
M	NULL
,	NULL
Misawa	NULL
H	NULL
,	NULL
Miyajima	NULL
A	NULL
,	NULL
Yoshimura	NULL
A	NULL
:	NULL
CIS	NULL
,	NULL
a	NULL
cytokine	NULL
inducible	NULL
SH2	NULL
protein	NULL
,	NULL
is	NULL
a	NULL
target	NULL
of	NULL
the	NULL
JAK-STATS	NULL
pathway	NULL
and	NULL
modulates	NULL
STATS	NULL
activation	NULL
.	NULL

Blood	NULL
89:3148	NULL
,	NULL
1997	NULL
19	NULL
.	NULL

Wang	NULL
D	NULL
,	NULL
Stravopodis	NULL
D	NULL
,	NULL
Teglund	NULL
S	NULL
,	NULL
Kitazawa	NULL
J	NULL
,	NULL
Thle	NULL
JN	NULL
:	NULL
Naturally	NULL
occurring	NULL
dominant	NULL
negative	NULL
variants	NULL
of	NULL
Stat5	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
16:6141	NULL
,	NULL
1996	NULL
20	NULL
.	NULL

Damen	NULL
JE	NULL
,	NULL
Wakao	NULL
H	NULL
,	NULL
Miyajima	NULL
A	NULL
,	NULL
Krosi	NULL
J	NULL
,	NULL
Humphries	NULL
RK	NULL
,	NULL
Cutler	NULL
RL	NULL
,	NULL
Krystal	NULL
G	NULL
:	NULL
Tyrosine	NULL
343	NULL
in	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
positively	NULL
regulates	NULL
erythropoietin-induced	NULL
cell	NULL
proliferation	NULL
and	NULL
Stat5	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
14:5557	NULL
,	NULL
1995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

ADDITIONAL	NULL
FACTOR	NULL
NEEDED	NULL
FOR	NULL
EPOR	NULL
SIGNALING	NULL
21	NULL
.	NULL

Chrétien	NULL
S	NULL
,	NULL
Varlet	NULL
P	NULL
,	NULL
Verdier	NULL
F	NULL
,	NULL
Gobert	NULL
S	NULL
,	NULL
Cartron	NULL
J-P	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Mayeux	NULL
P	NULL
,	NULL
Lacombe	NULL
C	NULL
:	NULL
Erythropoietin-induced	NULL
erythroid	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
TF-1	NULL
correlates	NULL
with	NULL
impaired	NULL
STATS	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
4174	NULL
,	NULL
1996	NULL
22	NULL
.	NULL

Iwatsuki	NULL
K	NULL
,	NULL
Endo	NULL
T	NULL
,	NULL
Misawa	NULL
H	NULL
,	NULL
Yokouchi	NULL
M	NULL
,	NULL
Matsumoto	NULL
A	NULL
,	NULL
Ohtsuhbo	NULL
M	NULL
,	NULL
Mori	NULL
KJ	NULL
,	NULL
Yoshimura	NULL
A	NULL
:	NULL
STATS	NULL
activation	NULL
correlates	NULL
with	NULL
erythropoietin	NULL
receptor-mediated	NULL
erythroid	NULL
differentiation	NULL
of	NULL
an	NULL
erythroleukemia	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:8149	NULL
,	NULL
1997	NULL
23	NULL
.	NULL

Liu	NULL
X	NULL
,	NULL
Robinson	NULL
GW	NULL
,	NULL
Wagner	NULL
K	NULL
,	NULL
Garrett	NULL
L	NULL
,	NULL
Wynshaw-Boris	NULL
A	NULL
,	NULL
Hennighausen	NULL
L	NULL
:	NULL
StatSa	NULL
is	NULL
mandatory	NULL
for	NULL
adult	NULL
mammary	NULL
gland	NULL
development	NULL
and	NULL
lactogenesis	NULL
.	NULL

Genes	NULL
Dev	NULL
11:179	NULL
,	NULL
1997	NULL
24	NULL
.	NULL

Udy	NULL
GB	NULL
,	NULL
Towers	NULL
RP	NULL
,	NULL
Snell	NULL
RG	NULL
,	NULL
Wilkins	NULL
RJ	NULL
,	NULL
Park	NULL
S-H	NULL
,	NULL
Ram	NULL
PA	NULL
,	NULL
Waxman	NULL
DJ	NULL
,	NULL
Davey	NULL
HW	NULL
:	NULL
Requirement	NULL
of	NULL
STAT	NULL
5b	NULL
for	NULL
sexual	NULL
dimor-phism	NULL
of	NULL
body	NULL
growth	NULL
rates	NULL
and	NULL
liver	NULL
gene	NULL
expression	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
94:7239	NULL
,	NULL
1997	NULL
25	NULL
.	NULL

Teglund	NULL
S	NULL
,	NULL
McKay	NULL
C	NULL
,	NULL
Schuetz	NULL
E	NULL
,	NULL
van	NULL
Deursen	NULL
JM	NULL
,	NULL
Stravopodis	NULL
D	NULL
,	NULL
Wang	NULL
D	NULL
,	NULL
Brown	NULL
M	NULL
,	NULL
Bodner	NULL
S	NULL
,	NULL
Grosveld	NULL
G	NULL
,	NULL
Ihle	NULL
JN	NULL
:	NULL
StatSa	NULL
and	NULL
StatSb	NULL
proteins	NULL
have	NULL
essential	NULL
and	NULL
nonessential	NULL
,	NULL
or	NULL
redundant	NULL
,	NULL
roles	NULL
in	NULL
cytokine	NULL
responses	NULL
.	NULL

Cell	NULL
93:841	NULL
,	NULL
1998	NULL
26	NULL
.	NULL

Neel	NULL
BG	NULL
,	NULL
Tonks	NULL
NK	NULL
:	NULL
Protein	NULL
tyrosine	NULL
phosphatases	NULL
in	NULL
signal	NULL
transduction	NULL
.	NULL

Curr	NULL
Opin	NULL
Cell	NULL
Biol	NULL
9:193	NULL
,	NULL
1997	NULL
27	NULL
.	NULL

Gaffen	NULL
SL	NULL
,	NULL
Goldsmith	NULL
MA	NULL
,	NULL
Greene	NULL
WC	NULL
:	NULL
in	NULL
A.	NULL
Thomson	NULL
(	NULL
ed	NULL
)	NULL
:	NULL
The	NULL
Cytokine	NULL
Handbook	NULL
(	NULL
ed	NULL
3	NULL
)	NULL
.	NULL

London	NULL
,	NULL
UK	NULL
,	NULL
Academic	NULL
,	NULL
1998	NULL
,	NULL
p	NULL
73	NULL
28	NULL
.	NULL

Goldsmith	NULL
MA	NULL
,	NULL
Lai	NULL
SY	NULL
,	NULL
Xu	NULL
W	NULL
,	NULL
Amaral	NULL
MC	NULL
,	NULL
Kuczek	NULL
ES	NULL
,	NULL
Parent	NULL
LJ	NULL
,	NULL
Mills	NULL
GB	NULL
,	NULL
Tarr	NULL
KL	NULL
,	NULL
Longmore	NULL
GD	NULL
,	NULL
Greene	NULL
WC	NULL
:	NULL
Growth	NULL
signal	NULL
transduction	NULL
by	NULL
the	NULL
human	NULL
IL-2	NULL
receptor	NULL
requires	NULL
cytoplasmic	NULL
tyrosines	NULL
of	NULL
the	NULL
B	NULL
chain	NULL
and	NULL
non-tyrosine	NULL
residues	NULL
of	NULL
the	NULL
yc	NULL
chain	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:21729	NULL
,	NULL
1995	NULL
29	NULL
.	NULL

Lai	NULL
SY	NULL
,	NULL
Xu	NULL
W	NULL
,	NULL
Gaffen	NULL
S	NULL
,	NULL
Liu	NULL
KD	NULL
,	NULL
Greene	NULL
WC	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
The	NULL
determinants	NULL
of	NULL
signal	NULL
transduction	NULL
specificity	NULL
in	NULL
yc-containing	NULL
cytokine	NULL
receptors	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:231	NULL
,	NULL
1996	NULL
30	NULL
.	NULL

Wang	NULL
L-M	NULL
,	NULL
Myers	NULL
MG	NULL
,	NULL
Sun	NULL
X-J	NULL
,	NULL
Aaronson	NULL
SA	NULL
,	NULL
White	NULL
M	NULL
,	NULL
Pierce	NULL
JH	NULL
:	NULL
IRS-1	NULL
:	NULL
Essential	NULL
for	NULL
insulin-	NULL
and	NULL
IL-4-stimulated	NULL
mitogenesis	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Science	NULL
261:1591	NULL
,	NULL
1993	NULL
31	NULL
.	NULL

Goldsmith	NULL
MA	NULL
,	NULL
Xu	NULL
W	NULL
,	NULL
Amaral	NULL
MC	NULL
,	NULL
Kuczek	NULL
ES	NULL
,	NULL
Greene	NULL
WC	NULL
:	NULL
The	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
B	NULL
chain	NULL
contains	NULL
both	NULL
unique	NULL
and	NULL
functionally	NULL
redundant	NULL
signal	NULL
transduction	NULL
elements	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
269:14698	NULL
,	NULL
1994	NULL
32	NULL
.	NULL

Ernst	NULL
J	NULL
,	NULL
Yang	NULL
L	NULL
,	NULL
Rosales	NULL
J	NULL
,	NULL
Broaddus	NULL
V	NULL
:	NULL
Preparation	NULL
and	NULL
characterization	NULL
of	NULL
an	NULL
endogenously	NULL
fluorescent	NULL
annexin	NULL
for	NULL
detection	NULL
of	NULL
apoptotic	NULL
cells	NULL
.	NULL

Anal	NULL
Biochem	NULL
260:18	NULL
,	NULL
1998	NULL
33	NULL
.	NULL

Yoshimura	NULL
A	NULL
,	NULL
D'Andrea	NULL
AD	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Friend	NULL
spleen	NULL
focus-forming	NULL
virus	NULL
glycoprotein	NULL
gpS55	NULL
interacts	NULL
with	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
in	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
and	NULL
affects	NULL
receptor	NULL
metabolism	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
87:4139	NULL
,	NULL
1990	NULL
34	NULL
.	NULL

Gaffen	NULL
SL	NULL
,	NULL
Lai	NULL
SY	NULL
,	NULL
Ha	NULL
M	NULL
,	NULL
Liu	NULL
X	NULL
,	NULL
Hennighausen	NULL
L	NULL
,	NULL
Greene	NULL
WC	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
Distinct	NULL
tyrosine	NULL
residues	NULL
within	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
B	NULL
chain	NULL
drive	NULL
signal	NULL
transduction	NULL
specificity	NULL
,	NULL
redundancy	NULL
,	NULL
and	NULL
diversity	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:21381	NULL
,	NULL
1996	NULL
35	NULL
.	NULL

Latchman	NULL
DS	NULL
,	NULL
in	NULL
Rickwood	NULL
D	NULL
,	NULL
Hames	NULL
BD	NULL
(	NULL
eds	NULL
)	NULL
:	NULL
Transcription	NULL
Factors	NULL
:	NULL
A	NULL
Practical	NULL
Approach	NULL
.	NULL

New	NULL
York	NULL
,	NULL
NY	NULL
,	NULL
IRL	NULL
,	NULL
1993	NULL
36	NULL
.	NULL

Gaffen	NULL
SL	NULL
,	NULL
Lai	NULL
SY	NULL
,	NULL
Xu	NULL
W	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Goldsmith	NULL
MA	NULL
,	NULL
Greene	NULL
WC	NULL
:	NULL
Signaling	NULL
through	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
activates	NULL
a	NULL
STAT-5-like	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92:7192	NULL
,	NULL
1995	NULL
37	NULL
.	NULL

Lamson	NULL
G	NULL
,	NULL
Koshland	NULL
ME	NULL
:	NULL
Changes	NULL
in	NULL
J	NULL
chain	NULL
and	NULL
u	NULL
chain	NULL
RNA	NULL
expression	NULL
as	NULL
a	NULL
function	NULL
of	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
160:877	NULL
,	NULL
1984	NULL
38	NULL
.	NULL

Boise	NULL
LH	NULL
,	NULL
Gonzalez-Garcia	NULL
M	NULL
,	NULL
Postema	NULL
CE	NULL
,	NULL
Ding	NULL
L	NULL
,	NULL
Lindsten	NULL
T	NULL
,	NULL
Turka	NULL
LA	NULL
,	NULL
Mao	NULL
X	NULL
,	NULL
Nufiez	NULL
G	NULL
,	NULL
Thompson	NULL
CB	NULL
:	NULL
Bci-x	NULL
,	NULL
a	NULL
bei-2-related	NULL
gene	NULL
that	NULL
functions	NULL
as	NULL
a	NULL
dominant	NULL
regulator	NULL
of	NULL
apoptotic	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
74:597	NULL
,	NULL
1993	NULL
39	NULL
.	NULL

Goldsmith	NULL
MA	NULL
,	NULL
Dazin	NULL
PF	NULL
,	NULL
Weiss	NULL
A	NULL
:	NULL
At	NULL
least	NULL
two	NULL
non-antigen	NULL
binding	NULL
molecules	NULL
are	NULL
required	NULL
for	NULL
signal	NULL
transduction	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
85:8613	NULL
,	NULL
1988	NULL
85	NULL
40	NULL
.	NULL

Koury	NULL
MJ	NULL
,	NULL
Bondurant	NULL
MC	NULL
:	NULL
Maintenance	NULL
by	NULL
erythropoietin	NULL
of	NULL
viablity	NULL
and	NULL
maturation	NULL
of	NULL
murine	NULL
erythroid	NULL
precursor	NULL
cells	NULL
.	NULL

J	NULL
Cell	NULL
Physiol	NULL
137:65	NULL
,	NULL
1988	NULL
41	NULL
.	NULL

Koury	NULL
MJ	NULL
,	NULL
Bondurant	NULL
MC	NULL
:	NULL
Erythropoietin	NULL
retards	NULL
DNA	NULL
breakdown	NULL
and	NULL
precents	NULL
programmed	NULL
cell	NULL
death	NULL
in	NULL
erythroid	NULL
progenitor	NULL
cells	NULL
.	NULL

Science	NULL
248:378	NULL
,	NULL
1990	NULL
42	NULL
.	NULL

Bauer	NULL
J	NULL
,	NULL
Liu	NULL
KD	NULL
,	NULL
Lai	NULL
SY	NULL
,	NULL
You	NULL
Y	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
Heteromeriza-tion	NULL
of	NULL
the	NULL
y	NULL
(	NULL
c	NULL
)	NULL
chain	NULL
with	NULL
the	NULL
interleukin-9	NULL
receptor	NULL
a	NULL
subunit	NULL
leads	NULL
to	NULL
STAT	NULL
activation	NULL
and	NULL
prevention	NULL
of	NULL
apoptosis	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
273:9255	NULL
,	NULL
1998	NULL
43	NULL
.	NULL

Martin	NULL
JS	NULL
,	NULL
Reutelingsperger	NULL
CPM	NULL
,	NULL
McGahon	NULL
AJ	NULL
,	NULL
Rader	NULL
JA	NULL
,	NULL
van	NULL
Schie	NULL
DM	NULL
,	NULL
LaFace	NULL
DM	NULL
,	NULL
Green	NULL
DR	NULL
:	NULL
Early	NULL
redistribution	NULL
of	NULL
plasma	NULL
membrane	NULL
phosphatidylserine	NULL
is	NULL
a	NULL
general	NULL
feature	NULL
of	NULL
apoptosis	NULL
regardless	NULL
of	NULL
the	NULL
initiating	NULL
stimulus	NULL
:	NULL
Inhibition	NULL
by	NULL
overexpression	NULL
of	NULL
Bcel-2	NULL
and	NULL
Abl	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
182:1545	NULL
,	NULL
1995	NULL
44	NULL
.	NULL

Koopman	NULL
G	NULL
,	NULL
Reutelingsperger	NULL
CPM	NULL
,	NULL
Kuijten	NULL
GAM	NULL
,	NULL
Keehnen	NULL
RMJ	NULL
,	NULL
Pals	NULL
ST	NULL
,	NULL
van	NULL
Oers	NULL
MHJ	NULL
:	NULL
Annexin	NULL
V	NULL
for	NULL
flow	NULL
cytometric	NULL
detection	NULL
of	NULL
phosphatidylserine	NULL
expression	NULL
on	NULL
B	NULL
cells	NULL
undergoing	NULL
apoptosis	NULL
.	NULL

Blood	NULL
84:1415	NULL
,	NULL
1994	NULL
45	NULL
.	NULL

Longmore	NULL
G	NULL
,	NULL
You	NULL
Y	NULL
,	NULL
Molden	NULL
J	NULL
,	NULL
Liu	NULL
K	NULL
,	NULL
Mikami	NULL
A	NULL
,	NULL
Lai	NULL
SY	NULL
,	NULL
Pharr	NULL
P	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
Redundant	NULL
and	NULL
selective	NULL
roles	NULL
for	NULL
erythropoietin	NULL
receptor	NULL
tyrosines	NULL
in	NULL
erythropoiesis	NULL
in	NULL
vivo	NULL
.	NULL

Blood	NULL
91:870	NULL
,	NULL
1998	NULL
46	NULL
.	NULL

Darnell	NULL
JE	NULL
,	NULL
Kerr	NULL
IM	NULL
,	NULL
Stark	NULL
GR	NULL
:	NULL
Jak-STAT	NULL
pathways	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IFNs	NULL
and	NULL
other	NULL
extracellular	NULL
signaling	NULL
proteins	NULL
.	NULL

Science	NULL
264:1415	NULL
,	NULL
1994	NULL
47	NULL
.	NULL

Kirito	NULL
K	NULL
,	NULL
Uchida	NULL
M	NULL
,	NULL
Yamada	NULL
M	NULL
,	NULL
Miura	NULL
Y	NULL
,	NULL
Komatsu	NULL
N	NULL
:	NULL
A	NULL
distinct	NULL
function	NULL
of	NULL
STAT	NULL
proteins	NULL
in	NULL
erythropoietin	NULL
signal	NULL
transduction	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:16507	NULL
,	NULL
1997	NULL
48	NULL
.	NULL

Quelle	NULL
FW	NULL
,	NULL
Wang	NULL
D	NULL
,	NULL
Nosaka	NULL
T	NULL
,	NULL
Thierfelder	NULL
WE	NULL
,	NULL
Stravopodis	NULL
D	NULL
,	NULL
Weinstein	NULL
Y	NULL
,	NULL
Ihle	NULL
JN	NULL
:	NULL
Erythropoietin	NULL
induces	NULL
activation	NULL
of	NULL
Stat5	NULL
through	NULL
association	NULL
with	NULL
specific	NULL
tyrosines	NULL
on	NULL
the	NULL
receptor	NULL
that	NULL
are	NULL
not	NULL
required	NULL
for	NULL
a	NULL
mitogenic	NULL
response	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
16:1622	NULL
,	NULL
1996	NULL
49	NULL
.	NULL

Packham	NULL
G	NULL
,	NULL
White	NULL
EL	NULL
,	NULL
Eischen	NULL
CM	NULL
,	NULL
Yang	NULL
H	NULL
,	NULL
Parganas	NULL
E	NULL
,	NULL
Thle	NULL
JN	NULL
,	NULL
Grillot	NULL
DAM	NULL
,	NULL
Zambetti	NULL
GP	NULL
,	NULL
Nufiez	NULL
G	NULL
,	NULL
Cleveland	NULL
JL	NULL
:	NULL
Selective	NULL
regulation	NULL
of	NULL
bel-xL	NULL
by	NULL
a	NULL
Jak	NULL
kinase-dependent	NULL
pathway	NULL
is	NULL
bypassed	NULL
in	NULL
murine	NULL
hematopoictin	NULL
malignancies	NULL
.	NULL

Genes	NULL
Dev	NULL
12:2475	NULL
,	NULL
1998	NULL
50	NULL
.	NULL

Silva	NULL
M	NULL
,	NULL
Grillot	NULL
D	NULL
,	NULL
Benito	NULL
A	NULL
,	NULL
Richard	NULL
C	NULL
,	NULL
Nufiez	NULL
G	NULL
,	NULL
Fernandez-Luna	NULL
JL	NULL
:	NULL
Erythropoietin	NULL
can	NULL
promote	NULL
erythroid	NULL
progenitor	NULL
survival	NULL
by	NULL
repressing	NULL
apoptosis	NULL
through	NULL
bel-xL	NULL
and	NULL
bel-2	NULL
.	NULL

Blood	NULL
88:1576	NULL
,	NULL
1996	NULL
51	NULL
.	NULL

Watowich	NULL
SS	NULL
,	NULL
Wu	NULL
H	NULL
,	NULL
Socolovsky	NULL
M	NULL
,	NULL
Klingmuller	NULL
U	NULL
,	NULL
Constanti-nescu	NULL
SN	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Cytokine	NULL
receptor	NULL
signal	NULL
transduction	NULL
and	NULL
the	NULL
control	NULL
of	NULL
hematopoietic	NULL
cell	NULL
development	NULL
.	NULL

Annu	NULL
Rev	NULL
Cell	NULL
Dev	NULL
Biol	NULL
12:91	NULL
,	NULL
1996	NULL
52	NULL
.	NULL

Vaux	NULL
DL	NULL
,	NULL
Cory	NULL
S	NULL
,	NULL
Adam	NULL
JM	NULL
:	NULL
Bel-2	NULL
gene	NULL
promotes	NULL
haemopoietic	NULL
cell	NULL
survival	NULL
and	NULL
cooperates	NULL
with	NULL
c-myc	NULL
to	NULL
immortalize	NULL
pre-B	NULL
cells	NULL
.	NULL

Nature	NULL
335:440	NULL
,	NULL
1988	NULL
53	NULL
.	NULL

Williams	NULL
GT	NULL
,	NULL
Smith	NULL
CA	NULL
,	NULL
Spooncer	NULL
E	NULL
,	NULL
Dexter	NULL
TM	NULL
,	NULL
Taylor	NULL
DR	NULL
:	NULL
Haemopoietic	NULL
colony	NULL
stimulating	NULL
factors	NULL
promote	NULL
cell	NULL
survival	NULL
by	NULL
suppressing	NULL
apoptosis	NULL
.	NULL

Nature	NULL
343:76	NULL
,	NULL
1990	NULL
54	NULL
.	NULL

Kinoshita	NULL
T	NULL
,	NULL
Yokota	NULL
T	NULL
,	NULL
Arai	NULL
K-I	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
Suppression	NULL
of	NULL
apoptotic	NULL
death	NULL
in	NULL
hematopoietic	NULL
cells	NULL
by	NULL
signalling	NULL
through	NULL
the	NULL
IL-3/GM-CSF	NULL
receptors	NULL
.	NULL

EMBO	NULL
J	NULL
14:266	NULL
,	NULL
1995	NULL
55	NULL
.	NULL

Tilbrook	NULL
P	NULL
,	NULL
Bittorf	NULL
T	NULL
,	NULL
Busfield	NULL
S	NULL
,	NULL
Chappell	NULL
D	NULL
,	NULL
Klinken	NULL
S	NULL
:	NULL
Disrupted	NULL
signaling	NULL
in	NULL
a	NULL
mutant	NULL
J2E	NULL
cell	NULL
line	NULL
that	NULL
shows	NULL
enhanced	NULL
viability	NULL
,	NULL
but	NULL
does	NULL
not	NULL
proliferate	NULL
or	NULL
differentiate	NULL
,	NULL
with	NULL
erythropoietin	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
271:3453	NULL
,	NULL
1996	NULL
56	NULL
.	NULL

Lai	NULL
SY	NULL
,	NULL
Molden	NULL
J	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
The	NULL
shared	NULL
yc	NULL
subunit	NULL
within	NULL
the	NULL
human	NULL
interleukin-7	NULL
receptor	NULL
complex	NULL
:	NULL
A	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
X-linked	NULL
severe	NULL
combined	NULL
immunodeficiency	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
99:169	NULL
,	NULL
1997	NULL
57	NULL
.	NULL

Lai	NULL
SY	NULL
,	NULL
Molden	NULL
J	NULL
,	NULL
Liu	NULL
KD	NULL
,	NULL
Puck	NULL
JM	NULL
,	NULL
White	NULL
MD	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
Interleukin-4-specific	NULL
signal	NULL
transduction	NULL
events	NULL
are	NULL
driven	NULL
by	NULL
homo-typic	NULL
interactions	NULL
of	NULL
the	NULL
interleukin-4	NULL
receptor	NULL
«	NULL
subunit	NULL
.	NULL

EMBO	NULL
J	NULL
15:4506	NULL
,	NULL
1996	NULL
58	NULL
.	NULL

Zamorano	NULL
J	NULL
,	NULL
Wang	NULL
HY	NULL
,	NULL
Wang	NULL
R	NULL
,	NULL
Shi	NULL
Y	NULL
,	NULL
Longmore	NULL
GD	NULL
,	NULL
Keegan	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

86	NULL
AD	NULL
:	NULL
Regulation	NULL
of	NULL
cell	NULL
growth	NULL
by	NULL
IL-2	NULL
:	NULL
Role	NULL
of	NULL
STATS	NULL
in	NULL
protection	NULL
from	NULL
apoptosis	NULL
but	NULL
not	NULL
in	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

J	NULL
Immunol	NULL
160:3502	NULL
,	NULL
1998	NULL
59	NULL
.	NULL

Jacobs-Helber	NULL
SM	NULL
,	NULL
Wickrema	NULL
A	NULL
,	NULL
Birrer	NULL
MJ	NULL
,	NULL
Sawyer	NULL
ST	NULL
:	NULL
API	NULL
regulation	NULL
of	NULL
proliferation	NULL
and	NULL
initiation	NULL
of	NULL
apoptosis	NULL
in	NULL
erythropoietin-dependent	NULL
erythroid	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
18:3699	NULL
,	NULL
1998	NULL
60	NULL
.	NULL

Quelle	NULL
FW	NULL
,	NULL
Wang	NULL
J	NULL
,	NULL
Feng	NULL
J	NULL
,	NULL
Wang	NULL
D	NULL
,	NULL
Cleveland	NULL
JL	NULL
,	NULL
Thle	NULL
JN	NULL
,	NULL
Zambetti	NULL
GP	NULL
:	NULL
Cytokine	NULL
rescue	NULL
of	NULL
p53-dependent	NULL
apoptosis	NULL
and	NULL
cell	NULL
cycle	NULL
arrest	NULL
is	NULL
mediated	NULL
by	NULL
distinct	NULL
Jak	NULL
kinase	NULL
signaling	NULL
pathways	NULL
.	NULL

Genes	NULL
Dev	NULL
12:1099	NULL
,	NULL
1998	NULL
61	NULL
.	NULL

Fairbairn	NULL
LJ	NULL
,	NULL
Cowling	NULL
GJ	NULL
,	NULL
Reipert	NULL
BM	NULL
,	NULL
Dexter	NULL
TM	NULL
:	NULL
Suppression	NULL
of	NULL
apoptosis	NULL
allows	NULL
differentiation	NULL
and	NULL
development	NULL
of	NULL
a	NULL
multipotent	NULL
hemopoietic	NULL
cell	NULL
line	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
added	NULL
growth	NULL
factors	NULL
.	NULL

Cell	NULL
74:823	NULL
,	NULL
1993	NULL
62	NULL
.	NULL

Lacronique	NULL
V	NULL
,	NULL
Varlet	NULL
P	NULL
,	NULL
Mayeux	NULL
P	NULL
,	NULL
Porteu	NULL
A	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Kahn	NULL
A	NULL
,	NULL
Lacombe	NULL
C	NULL
:	NULL
Bel-2	NULL
targeted	NULL
overexpression	NULL
into	NULL
the	NULL
erythroid	NULL
lineage	NULL
of	NULL
transgenic	NULL
mice	NULL
delays	NULL
but	NULL
does	NULL
not	NULL
prevent	NULL
the	NULL
apoptosis	NULL
of	NULL
erythropoietin-derprived	NULL
erythroid	NULL
progenitors	NULL
.	NULL

Blood	NULL
90:3050	NULL
,	NULL
1997	NULL
63	NULL
.	NULL

Hockenberry	NULL
D	NULL
,	NULL
Zutter	NULL
M	NULL
,	NULL
Hickey	NULL
W	NULL
,	NULL
Nahm	NULL
M	NULL
,	NULL
Korsmeyer	NULL
S	NULL
:	NULL
BCL2	NULL
protein	NULL
is	NULL
topologically	NULL
restricted	NULL
in	NULL
tissues	NULL
characterized	NULL
by	NULL
apoptotic	NULL
cell	NULL
death	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88:6961	NULL
,	NULL
1991	NULL
64	NULL
.	NULL

Kondo	NULL
M	NULL
,	NULL
Akashi	NULL
K	NULL
,	NULL
Domen	NULL
J	NULL
,	NULL
Sugamura	NULL
K	NULL
,	NULL
Weissman	NULL
IL	NULL
:	NULL
Bel-2	NULL
rescues	NULL
T	NULL
lymphopoiesis	NULL
but	NULL
not	NULL
B	NULL
or	NULL
NK	NULL
cell	NULL
development	NULL
,	NULL
in	NULL
common	NULL
ry	NULL
chain-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
7:155	NULL
,	NULL
1997	NULL
65	NULL
.	NULL

Akashi	NULL
K	NULL
,	NULL
Kondo	NULL
M	NULL
,	NULL
von	NULL
Freeden-Jeffry	NULL
U	NULL
,	NULL
Murray	NULL
R	NULL
,	NULL
Weissman	NULL
IL	NULL
:	NULL
Bcel-2	NULL
rescues	NULL
T	NULL
lymphopoiesis	NULL
in	NULL
interleukin-7	NULL
receptor-deficient	NULL
mice	NULL
.	NULL

Cell	NULL
89:1033	NULL
,	NULL
1997	NULL
66	NULL
.	NULL

Maraskovsky	NULL
E	NULL
,	NULL
O'Reilly	NULL
LA	NULL
,	NULL
Teepe	NULL
M	NULL
,	NULL
Corcoran	NULL
LM	NULL
,	NULL
Peschon	NULL
JJ	NULL
,	NULL
Strasser	NULL
A	NULL
:	NULL
Bcel-2	NULL
can	NULL
rescue	NULL
T	NULL
lymphocyte	NULL
development	NULL
in	NULL
interleukin-7	NULL
receptor-deficient	NULL
mice	NULL
but	NULL
not	NULL
in	NULL
mutant	NULL
rag-1~'~	NULL
mice	NULL
.	NULL

Cell	NULL
89:1011	NULL
,	NULL
1997	NULL
67	NULL
.	NULL

Peschon	NULL
JJ	NULL
,	NULL
Morrissey	NULL
PJ	NULL
,	NULL
Grabstein	NULL
KH	NULL
,	NULL
Ramsdell	NULL
FJ	NULL
,	NULL
Maraskovsky	NULL
E	NULL
,	NULL
Gliniak	NULL
BC	NULL
,	NULL
Park	NULL
LS	NULL
,	NULL
Ziegler	NULL
SF	NULL
,	NULL
Williams	NULL
DE	NULL
,	NULL
Ware	NULL
CB	NULL
,	NULL
Meyer	NULL
JD	NULL
,	NULL
Davison	NULL
BL	NULL
:	NULL
Early	NULL
lymphocyte	NULL
expansion	NULL
is	NULL
severely	NULL
impaired	NULL
in	NULL
interleukin	NULL
7	NULL
receptor-deficient	NULL
mice	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
180:1955	NULL
,	NULL
1994	NULL
68	NULL
.	NULL

Klingmuller	NULL
U	NULL
,	NULL
Bergelson	NULL
S	NULL
,	NULL
Hsiao	NULL
JG	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
Multiple	NULL
tyrosine	NULL
residues	NULL
in	NULL
the	NULL
cytosolic	NULL
domain	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
promote	NULL
activation	NULL
of	NULL
STAT	NULL
5	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
93:8324	NULL
,	NULL
1996	NULL
69	NULL
.	NULL

Gobert	NULL
S	NULL
,	NULL
Chretien	NULL
S	NULL
,	NULL
Gouilleux	NULL
F	NULL
,	NULL
Muller	NULL
O	NULL
,	NULL
Pallard	NULL
C	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Groner	NULL
B	NULL
,	NULL
Lacombe	NULL
C	NULL
,	NULL
Gisselbrecht	NULL
S	NULL
,	NULL
Mayeux	NULL
P	NULL
:	NULL
Identification	NULL
of	NULL
tyrosine	NULL
residues	NULL
within	NULL
the	NULL
intracellular	NULL
domain	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
crucial	NULL
for	NULL
STATS	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
15:2434	NULL
,	NULL
1996	NULL
70	NULL
.	NULL

Dong	NULL
YJ	NULL
,	NULL
Goldwasser	NULL
E	NULL
:	NULL
Evidence	NULL
for	NULL
an	NULL
accessory	NULL
component	NULL
that	NULL
increases	NULL
the	NULL
affinity	NULL
of	NULL
the	NULL
erythropoietin	NULL
receptor	NULL
.	NULL

Exp	NULL
Hematol	NULL
21:483	NULL
,	NULL
1993	NULL
71	NULL
.	NULL

Krystal	NULL
G	NULL
,	NULL
Humphries	NULL
K	NULL
,	NULL
Damen	NULL
J	NULL
:	NULL
;	NULL
A	NULL
second	NULL
erythropoietin	NULL
receptor	NULL
subunit	NULL
.	NULL

Blood	NULL
85:2641	NULL
,	NULL
1995	NULL
GAFFEN	NULL
ET	NULL
AL	NULL
72	NULL
.	NULL

Yoshimura	NULL
A	NULL
:	NULL
Second	NULL
subunit	NULL
of	NULL
the	NULL
EPO	NULL
receptor	NULL
?	NULL

Nature	NULL
372137	NULL
,	NULL
1994	NULL
73	NULL
.	NULL

Masuda	NULL
S	NULL
,	NULL
Nagao	NULL
M	NULL
,	NULL
Takahata	NULL
K	NULL
,	NULL
Konishi	NULL
Y	NULL
,	NULL
Gallyas	NULL
F	NULL
,	NULL
Tabira	NULL
T	NULL
,	NULL
Sasaki	NULL
R	NULL
:	NULL
Functional	NULL
erythropoietin	NULL
receptor	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
neural	NULL
characteristics	NULL
.	NULL

Comparison	NULL
with	NULL
receptor	NULL
properties	NULL
of	NULL
erythroid	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
268:11208	NULL
,	NULL
1993	NULL
74	NULL
.	NULL

Evans	NULL
G	NULL
,	NULL
Goldsmith	NULL
MA	NULL
,	NULL
Johnston	NULL
JA	NULL
,	NULL
Xu	NULL
W	NULL
,	NULL
Weiler	NULL
SR	NULL
,	NULL
Erwin	NULL
R	NULL
,	NULL
Howard	NULL
OMZ	NULL
,	NULL
Abraham	NULL
RT	NULL
,	NULL
O'Shea	NULL
JJ	NULL
,	NULL
Greene	NULL
WC	NULL
,	NULL
Farrar	NULL
WL	NULL
:	NULL
Analysis	NULL
of	NULL
interleukin-2-dependent	NULL
signal	NULL
transduction	NULL
through	NULL
the	NULL
Shc/Grb2	NULL
adapter	NULL
pathway	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
270:28858	NULL
,	NULL
1995	NULL
75	NULL
.	NULL

Liu	NULL
KD	NULL
,	NULL
Greene	NULL
WC	NULL
,	NULL
Goldsmith	NULL
MA	NULL
:	NULL
Relationship	NULL
of	NULL
IL-2	NULL
receptor	NULL
tyrosines	NULL
to	NULL
pathways	NULL
linked	NULL
to	NULL
phosphatidyl-3'-kinase	NULL
and	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
.	NULL

(	NULL
submitted	NULL
)	NULL
76	NULL
.	NULL

Barber	NULL
DL	NULL
,	NULL
Corless	NULL
CN	NULL
,	NULL
Xia	NULL
K	NULL
,	NULL
Roberts	NULL
TM	NULL
,	NULL
D'Andrea	NULL
AA	NULL
:	NULL
Erythropoietin	NULL
activates	NULL
Rafl	NULL
by	NULL
a	NULL
Shc-independent	NULL
pathway	NULL
in	NULL
CTLL-EPO-R	NULL
cells	NULL
.	NULL

Blood	NULL
89:55	NULL
,	NULL
1997	NULL
77	NULL
.	NULL

Shultz	NULL
LD	NULL
,	NULL
Schweitzer	NULL
PA	NULL
,	NULL
Rajan	NULL
TV	NULL
,	NULL
Yi	NULL
T	NULL
,	NULL
Thile	NULL
J	NULL
,	NULL
Matthews	NULL
RJ	NULL
,	NULL
Thomas	NULL
ML	NULL
,	NULL
Beier	NULL
DR	NULL
:	NULL
Mutations	NULL
at	NULL
the	NULL
murine	NULL
motheaten	NULL
locus	NULL
are	NULL
within	NULL
the	NULL
hematopoietic	NULL
cell	NULL
protein-tyrosine	NULL
phosphatase	NULL
(	NULL
Heph	NULL
)	NULL
gene	NULL
.	NULL

Cell	NULL
73:1445	NULL
,	NULL
1993	NULL
78	NULL
.	NULL

Tsui	NULL
HW	NULL
,	NULL
Siminovitch	NULL
KA	NULL
,	NULL
deSouza	NULL
L	NULL
,	NULL
Tsui	NULL
FWL	NULL
:	NULL
Motheaten	NULL
and	NULL
viable	NULL
motheaten	NULL
mice	NULL
have	NULL
mutations	NULL
in	NULL
the	NULL
hematopoietic	NULL
cell	NULL
phosphatase	NULL
gene	NULL
.	NULL

Nat	NULL
Genet	NULL
4:124	NULL
,	NULL
1993	NULL
79	NULL
.	NULL

Aman	NULL
MJ	NULL
,	NULL
Leonard	NULL
WJ	NULL
:	NULL
Cytokine	NULL
signaling	NULL
:	NULL
Cytokine-inducible	NULL
signaling	NULL
inhibitors	NULL
.	NULL

Curr	NULL
Biol	NULL
7	NULL
:	NULL
R784	NULL
,	NULL
1997	NULL
80	NULL
.	NULL

Naka	NULL
T	NULL
,	NULL
Narazaki	NULL
M	NULL
,	NULL
Hirata	NULL
M	NULL
,	NULL
Matsumoto	NULL
T	NULL
,	NULL
Minamoto	NULL
S	NULL
,	NULL
Aono	NULL
A	NULL
,	NULL
Nishimoto	NULL
N	NULL
,	NULL
Kajita	NULL
T	NULL
,	NULL
Taga	NULL
T	NULL
,	NULL
Yoshizaki	NULL
K	NULL
,	NULL
Akira	NULL
S	NULL
,	NULL
Kishimoto	NULL
T	NULL
:	NULL
Structure	NULL
and	NULL
function	NULL
of	NULL
a	NULL
new	NULL
STAT-induced	NULL
STAT	NULL
inhibitor	NULL
.	NULL

Nature	NULL
387:924	NULL
,	NULL
1997	NULL
81	NULL
.	NULL

Yoshimura	NULL
A	NULL
,	NULL
Ohkubo	NULL
T	NULL
,	NULL
Kiguchi	NULL
T	NULL
,	NULL
Jenkins	NULL
NA	NULL
,	NULL
Gilbert	NULL
DJ	NULL
,	NULL
Copeland	NULL
NG	NULL
,	NULL
Hara	NULL
T	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
A	NULL
novel	NULL
cytokine-inducible	NULL
gene	NULL
CIS	NULL
encodes	NULL
an	NULL
SH2-containing	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
tyrosine-phosphorylated	NULL
interleukin	NULL
2	NULL
and	NULL
erythropoietin	NULL
receptors	NULL
.	NULL

EMBO	NULL
J	NULL
14:2816	NULL
,	NULL
1995	NULL
82	NULL
.	NULL

Goldsmith	NULL
MA	NULL
,	NULL
Mikami	NULL
A	NULL
,	NULL
You	NULL
Y	NULL
,	NULL
Liu	NULL
KD	NULL
,	NULL
Thomas	NULL
L	NULL
,	NULL
Pharr	NULL
P	NULL
,	NULL
Longmore	NULL
GD	NULL
:	NULL
Absence	NULL
of	NULL
cytokine	NULL
receptor-dependent	NULL
specificity	NULL
in	NULL
red	NULL
blood	NULL
cell	NULL
differentiation	NULL
in	NULL
vivo	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
95:7006	NULL
,	NULL
1998	NULL
83	NULL
.	NULL

Socolovsky	NULL
M	NULL
,	NULL
Dusanter-Fourt	NULL
I	NULL
,	NULL
Lodish	NULL
HF	NULL
:	NULL
The	NULL
prolactin	NULL
receptor	NULL
and	NULL
severely	NULL
truncated	NULL
erythropoietin	NULL
receptors	NULL
support	NULL
differentiation	NULL
of	NULL
erythroid	NULL
progenitors	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
272:14009	NULL
,	NULL
1997	NULL
84	NULL
.	NULL

Corcoran	NULL
AE	NULL
,	NULL
Smart	NULL
FM	NULL
,	NULL
Cowling	NULL
RJ	NULL
,	NULL
Crompton	NULL
T	NULL
,	NULL
Owen	NULL
MJ	NULL
,	NULL
Venkitaraman	NULL
AR	NULL
:	NULL
The	NULL
interleukin-7	NULL
receptor	NULL
«	NULL
chain	NULL
transmits	NULL
direct	NULL
signals	NULL
for	NULL
proliferation	NULL
and	NULL
differentiation	NULL
during	NULL
B	NULL
lymphopoiesis	NULL
.	NULL

EMBO	NULL
J	NULL
15:1924	NULL
,	NULL
1996	NULL
85	NULL
.	NULL

Wakao	NULL
H	NULL
,	NULL
Harada	NULL
N	NULL
,	NULL
Kitamura	NULL
T	NULL
,	NULL
Mui	NULL
AL-F	NULL
,	NULL
Miyajima	NULL
A	NULL
:	NULL
Interleukin	NULL
2	NULL
and	NULL
erythropoietin	NULL
activate	NULL
STATS/MGF	NULL
via	NULL
distinct	NULL
pathways	NULL
.	NULL

EMBO	NULL
J	NULL
14:2527	NULL
,	NULL
1995	NULL
From	NULL
www.bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

blood	NULL
~	NULL
Genetic	NULL
Evidence	NULL
for	NULL
an	NULL
Additional	NULL
Factor	NULL
Required	NULL
for	NULL
Erythropoietin-Induced	NULL
Signal	NULL
Transduction	NULL
Sarah	NULL
L.	NULL
Gaffen	NULL
,	NULL
Stephen	NULL
Y.	NULL
Lai	NULL
,	NULL
Gregory	NULL
D.	NULL
Longmore	NULL
,	NULL
Kathleen	NULL
D.	NULL
Liu	NULL
and	NULL
Mark	NULL
A.	NULL
Goldsmith	NULL
4	NULL
_	NULL
5	NULL
,	NULL
'	NULL
_	NULL
>	NULL
,	NULL
#	NULL
04	NULL
;	NULL
©1004	NULL
@	NULL
207	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/94/1/74.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Hematopoiesis	NULL
and	NULL
Stem	NULL
Cells	NULL
(	NULL
3573	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

